Anti-CD33 antibodies and methods of use thereof
Anti-CD33 antibodies with enhanced binding affinity and reduced EC50 are developed to target CD33 on human cells, addressing unwanted CD33 activity in diseases like Alzheimer's and cancer by reducing CD33 expression and modulating microglial markers.
Patent Information
- Application Number
- JP2021511561
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-08-31
- Filing Date
- 2019-08-30
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2039-08-30
AI Technical Summary
There is a need for therapeutic anti-CD33 antibodies to treat diseases and conditions associated with unwanted CD33 activity, as evidenced by the association of CD33 expression with both Alzheimer's disease and cancer outcomes.
Development of anti-CD33 antibodies with improved functional characteristics, such as higher affinity and lower EC50 for CD33, capable of reducing CD33 expression on human cells, including monoclonal, chimeric, humanized, and bispecific antibodies that target CD33 on various cell types.
The antibodies effectively bind to CD33, reducing its cell surface levels and potentially modulating disease-associated microglial markers, offering therapeutic potential for conditions like Alzheimer's disease and cancer.
Smart Images

Figure 0007586813000047 
Figure 0007586813000048 
Figure 0007586813000049
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 62 / 726,053, filed August 31, 2018, which is incorporated herein by reference in its entirety.
[0002] Submitting a sequence listing as an ASCII text file The contents of the following submission in an ASCII text file are incorporated herein by reference in their entirety: Sequence Listing in Computer Readable Form (CRF) (Filename: 735022002840SEQLIST.TXT, Recorded: August 26, 2019, Size: 112KB).
[0003] Technical Field of the Disclosure The present disclosure relates to anti-CD33 antibodies and therapeutic uses of such antibodies. [Background technology]
[0004] The myeloid cell surface antigen CD33 precursor (CD33), also known as Siglec-3, is a type 1 immunoglobulin-like transmembrane protein expressed on immune and hematopoietic cells, including immature and mature myeloid cells, dendritic cells, and microglial cells (Crocker et al. (2007) Nat Rev Immunol. 7:255-266; McMillan and Crocker (2008) Carbohydr Res. 343:2050-2056; Von Gunten and Bochner (2008) Ann NY Acad Sci. 1143:61-82; Handgretinger et al. (1993) Immunol Lett. 37:223-228; and Hernandez-Caselles et al. (2006) J Leukoc Biol. 79:46-58). CD33 contains an Ig-like C2-type (immunoglobulin-like) and an Ig-like V-type (immunoglobulin-like) extracellular domain and two ITIM-like motifs in its cytoplasmic domain. Three alternatively spliced forms (isoforms) of CD33 have been identified, including a high-molecular-weight variant designated CD33M, and a smaller isoform, CD33m, which lacks the Ig-like V-type domain (ligand-binding site) and the disulfide bond linking the V and C domains.
[0005] Genome-wide association studies (GWAS) conducted on extended cohorts (e.g., thousands of individuals) have identified the CD33 single nucleotide polymorphism (SNP) rs3865444 CC (also known as rs3826656) and rs3865444 AA has been identified as a genetic modifier of risk for late-onset Alzheimer's disease (AD). In oncology, CD33 variants resulting in reduced CD33 expression have been shown to be associated with improved survival in pediatric acute myeloid leukemia (AML). 3-year overall survival after remission was significantly improved by rs3865444, which is associated with reduced full-length CD33 expression. AA Variant rs35112940 in strong linkage disequilibrium with variant GGThe remission rate is 84% + / - 8% in carriers of the rs12459419 allele. For non-protective alleles, the remission rate is 68% + / - 15%. Carriers of protective alleles also have a lower risk of relapse and a higher disease-free survival rate. Similarly, patients homozygous for the minor variant allele (TT) of rs12459419, associated with a greater than 46% reduction in full-length CD33 expression, have a more favorable disease outcome than carriers of the CC and CT variants (52% vs. 31%) and are more likely to have significantly lower diagnostic blast CD33 expression than other genotypes. This is even true for patients treated with anti-CD33 antibodies and toxic calicheamicin gamma derivatives (Mortland et al., (2013) Clin Cancer Res; 1-8). 2459419 TT Allele carriers of rs12459419 show a greater than 25% reduction in full-length CD33 expression CT Like carriers of the allele, they also show a reduced risk of Alzheimer's disease (Malik M. et al. (2015) Human Molecular Genetics, 1-14). This suggests that reducing CD33 expression or function may be beneficial in Alzheimer's disease and cancer.
[0006] Antibodies against CD33 are described, for example, in US Pat. No. 7,342,110, US Pat. No. 7,557,189, US Pat. No. 8,119,787, US Pat. No. 8,337,855, US Pat. No. 8,124,069, US Pat. No. 5,730,982, WO2012 / 074097, WO2004 / 043344, WO1993 / 020848, WO2012 / 045752, WO2007 / 014743, WO2003 / 093298, WO2011 / 036183, WO1991 / 009058, WO2008 / 058021, WO2011 / 038301, WO2016 / 201389, WO2016 / 201388, Hoyer et al. al(2008) Am J Clin Pathol,129:316-323, Rollins-Ravel and Roth(2012) Histopathology 60:933-942, Perez-Olivia et al(2011) Glycobiol 21:757-770, Ferlasso et al(2000) Eur J Immunol 30:827-833, Vitale et al (2001) Proc Natl Acad Sci USA 98:5764-5769, Jandus et al (2011) Biochem Pharmacol 82:323-332, O'Reilly and Paulson (2009) Trends Pharmcol Sci 30:240-248, Jurcic (2012) Curr Hematol Malig Rep 7:65-73, and Ricart (2011) Clin Cancer Res 17:6417-6427.
[0007] Thus, there is a need for therapeutic anti-CD33 antibodies to treat diseases, disorders, and conditions associated with unwanted CD33 activity.
[0008] All references cited herein, including patents, patent applications, and publications, are hereby incorporated by reference in their entirety. Summary of the Invention
[0009] The present disclosure is generally directed to compositions comprising antibodies, e.g., monoclonal antibodies, chimeric antibodies, humanized antibodies, antibody fragments, etc., that specifically bind to human CD33, and methods of using such compositions.
[0010] Certain aspects of the present disclosure are based, at least in part, on the identification of anti-CD33 antibodies with improved and / or enhanced functional characteristics. In some embodiments, the anti-CD33 antibodies of the present disclosure comprise one or more improved and / or enhanced functional characteristics compared to a reference antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4). In some embodiments, the anti-CD33 antibodies of the present disclosure have a higher affinity for CD33 (e.g., human CD33) than that of the reference anti-CD33 antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4). In some embodiments, the anti-CD33 antibodies of the present disclosure have a lower median effective concentration (EC ) than that of the reference antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4). 50 ) to human cells, such as human primary dendritic cells. In some embodiments, the anti-CD33 antibodies of the present disclosure bind to human cells, such as human primary dendritic cells, at a median effective concentration (EC ) that is lower than that of a reference antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the sequence of SEQ ID NO: 3 and a light chain variable region comprising the sequence of SEQ ID NO: 4). 50 ) to reduce cellular levels of CD33 (e.g., reduce or lower cell surface levels).
[0011] Thus, in one aspect, the present disclosure relates to an antibody that binds to CD33 protein, the antibody comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HVR-H1 comprising an amino acid sequence selected from SEQ ID NOs: 8 to 30, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprising an amino acid sequence selected from SEQ ID NOs: 39 to 40, HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprising an amino acid sequence selected from SEQ ID NOs: 53 to 55, and HVR-L3 comprising an amino acid sequence selected from SEQ ID NOs: 58 to 62.
[0012] In another aspect, the disclosure provides an antibody that binds to a CD33 protein, the antibody comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region is selected from the group consisting of antibodies 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H
[0023] The present invention relates to an antibody comprising HVR-H1, HVR-H2, and HVR-H3 of 6C7H50, 6C7H51, 6C7H52, 6C7H53, or 6C7H54.
[0013] In another aspect, the disclosure provides an antibody that binds to a CD33 protein, the antibody comprising a heavy chain variable region and a light chain variable region, wherein the light chain variable region is selected from the group consisting of antibodies 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H
[0023] The present invention relates to an antibody comprising HVR-L1, HVR-L2, and HVR-L3 of 6C7H50, 6C7H51, 6C7H52, 6C7H53, or 6C7H54.
[0014] In another aspect, the disclosure provides an antibody that binds to a CD33 protein, the antibody comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region is selected from the group consisting of antibodies 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, 6C7H54, 6C7H55, 6C7H56, 6C7H57, 6C7H58, 6C7H59, 6C7H60, 6C7H61, 6C7H62, 6C7H63, 6C7H64, 6C7H65, H in C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, or 6C7H54 and the light chain variable region comprises HVR-H1, HVR-H2, and HVR-H3 of antibodies 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, 6C7H54, 6C7H55, 6C7H56, 6C7H57, 6C7H58, 6C7H59, 6C7H60, 6C7H61, 6C7H62, 6C7H63, 6C7H64, 6C7H65, 6C7H66, 6C7H67, 6C7H6
[0023] The present invention relates to an antibody comprising HVR-L1, HVR-L2, and HVR-L3 of any of the following: 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, or 6C7H54.
[0015] In another aspect, the present disclosure provides an antibody that binds to CD33 protein, the antibody being selected from the group consisting of antibodies 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, 6C7H54, 6C7H55, 6C7H56, 6C7H57, 6C7H58, 6C7H59, 6C7H60, 6C7H61, 6C7H62, 6C7H63, 6C7H64, 6C7H65, 6C7H66, 6C7H67, 6C7 8, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, or 6C7H 54 heavy chain variable regions, the antibodies being selected from the group consisting of antibodies 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H 31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, or 6C7H54.
[0016] In another aspect, the present disclosure relates to an antibody that binds to CD33 protein, the antibody comprising a heavy chain variable region comprising an amino acid sequence selected from SEQ ID NOs: 68-93 and / or a light chain variable region comprising an amino acid sequence selected from SEQ ID NOs: 97-103.
[0017] In another aspect, the present disclosure provides an antibody that binds to CD33 protein, the antibody being selected from the group consisting of antibodies 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, 6C7H54, 6C7H55, 6C7H56, 6C7H57, 6C7H58, 6C7H59, 6C7H60, 6C7H61, 6C7H62, 6C7H63, 6C7H64, 6C7H65, 6C7H66, 6C7H67, 6C7 8, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, or 6C7H 54 heavy chain variable regions, the antibodies being selected from the group consisting of antibodies 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H 31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, or 6C7H54.
[0018] In another aspect, the disclosure relates to an isolated antibody that binds to CD33, the antibody comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; and the light chain variable region comprises HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 61.
[0019] In another aspect, the disclosure relates to an isolated antibody that binds to CD33, the antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 83 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 102.
[0020] In another aspect, the disclosure provides an isolated antibody that binds to CD33, the antibody comprising: (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 120 and a light chain comprising the amino acid sequence of SEQ ID NO: 122, or (b) an isolated antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 121 and a light chain comprising the amino acid sequence of SEQ ID NO: 122.
[0021] In some embodiments that may be combined with any of the preceding embodiments, the heavy chain variable region comprises one, two, three, or four framework regions selected from VH FR1, VH FR2, VH FR3, and VH FR4, wherein VH FR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 5-6, VH FR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 31-32, VH FR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 34-36, and VH FR4 comprises the sequence of SEQ ID NO: 41; the light chain variable region comprises one, two, three, or four framework regions selected from VL FR1, VL FR2, VL FR3, and VL FR4, wherein VL FR1 comprises a sequence selected from the group consisting of SEQ ID NOs: 42-46, VL FR2 comprises a sequence selected from the group consisting of SEQ ID NOs: 48-51, and VL FR3 comprises a sequence selected from the group consisting of SEQ ID NOs: 56-57; FR4 comprises a sequence selected from the group consisting of SEQ ID NOs: 63-64.
[0022] In some embodiments that may be combined with any of the preceding embodiments, the antibody is of the IgG class, the IgM class, or the IgA class. In some embodiments, the antibody is of the IgG class and has an IgG1, IgG2, IgG3, or IgG4 isotype. In some embodiments, the antibody has an IgG4 isotype, and the antibody comprises a S228P amino acid substitution at residue position 228, a F234A amino acid substitution at residue position 234, and a L235A amino acid substitution at residue position 235, where the numbering of residue positions is according to EU numbering. In some embodiments, the antibody comprises one or more amino acid substitutions in the Fc region at residue positions selected from the group consisting of C127S, L234A, L234F, L235A, L235E, S267E, K322A, L328F, A330S, P331S, E345R, E430G, S440Y, and any combination thereof, where residue numbering is according to EU numbering.In some embodiments, the Fc region comprises an amino acid substitution at position E430G, where the numbering of the residue positions is according to EU numbering; or the Fc region comprises amino acid substitutions at positions L234A, L235A, and P331A, where the numbering of the residue positions is according to EU numbering; or the Fc region comprises amino acid substitutions at positions L234A, L235A, P331A, and E430G, where the numbering of the residue positions is according to EU numbering. , the Fc region comprises amino acid substitutions at positions K322A and E430G, where the numbering of the residue positions is according to EU numbering; or the Fc region comprises amino acid substitutions at positions P331S and E430G, where the numbering of the residue positions is according to EU numbering; or the Fc region comprises amino acid substitutions at positions A330S, P331S, and E430G, where the numbering of the residue positions is according to EU numbering; or the Fc region comprises amino acid substitutions at positions K322A, A330S the Fc region contains amino acid substitutions at positions K322A, P331S, and E430G, where the numbering of the residue positions is according to EU numbering; the Fc region contains amino acid substitutions at positions K322A, P331S, and E430G, where the numbering of the residue positions is according to EU numbering; the Fc region contains amino acid substitutions at position E430G, where the numbering of the residue positions is according to EU numbering; the Fc region contains amino acid substitutions at positions A330S, P331S, and E430G, where the numbering of the residue positions is according to EU numbering. The numbering of residue positions is according to EU numbering; the Fc region comprises amino acid substitutions at positions S267E and L328F and the numbering of residue positions is according to EU numbering; the Fc region comprises amino acid substitutions at position C127S and the numbering of residue positions is according to EU numbering; or the Fc region comprises amino acid substitutions at positions E345R, E430G, and S440Y and the numbering of residue positions is according to EU numbering.
[0023] In some embodiments that may be combined with any of the preceding embodiments, the CD33 protein is a mammalian or human protein. In some embodiments, the CD33 protein is a wild-type protein. In some embodiments, the CD33 protein is a naturally occurring variant. In some embodiments that may be combined with any of the preceding embodiments, the CD33 protein is expressed on one or more cells selected from the group consisting of human dendritic cells, human macrophages, human monocytes, human osteoclasts, human neutrophils, human T cells, human helper T cells, human cytotoxic T cells, human granulocytes, and human microglia.
[0024] In some embodiments that may be combined with any of the preceding embodiments, the antibody specifically binds to human CD33 protein. In some embodiments, the antibody binds to human CD33 protein and does not cross-react with CD33 orthologs or homologs from other species. In some embodiments that may be combined with any of the preceding embodiments, the antibody is an antibody fragment that binds to an epitope comprising amino acid residues on human CD33 or a mammalian CD33 protein. In some embodiments that may be combined with any of the preceding embodiments, the antibody is an antibody fragment that binds to one or more human proteins selected from the group consisting of human CD33, naturally occurring variants of human CD33, and disease variants of human CD33. In some embodiments, the antibody fragment is crosslinked to a second antibody fragment that binds to one or more human proteins selected from the group consisting of human CD33, naturally occurring variants of human CD33, and disease variants of human CD33. In some embodiments, the fragment is a Fab, Fab', Fab'-SH, F(ab')2, Fv, or scFv fragment.
[0025] In some embodiments that may be combined with any of the preceding embodiments, the antibody is a humanized antibody, a bispecific antibody, a monoclonal antibody, a multivalent antibody, a conjugated antibody, or a chimeric antibody. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a bispecific antibody that recognizes a first antigen and a second antigen. In some embodiments, the first antigen is CD33 and the second antigen is an antigen that promotes transport across the blood-brain barrier; an antigen that promotes transport across the blood-brain barrier selected from the group consisting of transferrin receptor (TR), insulin receptor (HIR), insulin-like growth factor receptor (IGFR), low-density lipoprotein receptor-related proteins 1 and 2 (LPR-1 and 2), diphtheria toxin receptor, CRM197, llama single-domain antibody, TMEM 30(A), protein transduction domains, TAT, Syn-B, penetratin, polyarginine peptides, angiopep peptides, and ANG1005;A pathogenic substance selected from the group consisting of a pathogenic peptide or protein and a pathogenic nucleic acid, wherein the pathogenic peptide or protein is amyloid beta, amyloid beta oligomer, amyloid beta plaque, amyloid precursor protein or a fragment thereof, tau, IAPP, α-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), c9RAN protein, prion protein, PrPSc, huntingtin, calcitonin, superoxide dismutase, ataxin, ataxin 1, or ataxin 2. , ataxin 3, ataxin 7, ataxin 8, ataxin 10, Lewy bodies, atrial natriuretic factor, islet amyloid polypeptide, insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, transthyretin, lysozyme, β2-microglobulin, gelsolin, keratoepithelin, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) translation products, dipeptide repeat (DPR) peptides, glycine-alanine (GA) repeat peptides, glycine-proline ( a pathogenic agent selected from the group consisting of a glycine-arginine (GR) repeat peptide, a proline-alanine (PA) repeat peptide, ubiquitin, and a proline-arginine (PR) repeat peptide, and the pathogenic nucleic acid is an antisense GGCCCC (G2C4) repeat-expanded RNA; a ligand and / or protein expressed on immune cells, such as CD40, OX40, ICOS, CD28, CD137 / 4-1BB, CD27, GITR, PD-L1, CTLA4, PD-L2, PD-1, B7-H3, a ligand and / or protein selected from the group consisting of B7-H4, HVEM, LIGHT, BTLA, CD38, TIGIT, VISTA, KIR, GAL9, TIM1, TIM3, TIM4, A2AR, LAG3, DR5, CD39, CD70, CD73, TREM1, TREM2, Siglec-5, Siglec-7, Siglec-9, Siglec-11, SirpA, CD47, CSF1-receptor, and phosphatidylserine; and a protein, lipid, polysaccharide, or glycolipid expressed on one or more tumor cells;
[0026] In some embodiments that may be combined with any of the preceding embodiments, the antibody is selected from the group consisting of a pathogenic peptide, a pathogenic protein, amyloid beta, amyloid beta oligomers, amyloid beta plaques, amyloid precursor protein or fragments thereof, tau, IAPP, α-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), prion protein, PrPSc, huntingtin, calcitonin, superoxide dismutase, ataxin, ataxin 1, ataxin 2, ataxin 3, amyloid precursor protein ... Taxin 7, ataxin 8, ataxin 10, Lewy bodies, atrial natriuretic factor, islet amyloid polypeptide, insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, transthyretin, lysozyme, β2-microglobulin, gelsolin, keratoepithelin, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) translation products, dipeptide repeat (DPR) peptides, glycine-alanine (GA) repeat peptides, glycine-proline (GP) lipids in combination with one or more antibodies that specifically bind to a pathogenic agent selected from the group consisting of a glycine-arginine (GR) repeat peptide, a proline-alanine (PA) repeat peptide, ubiquitin, and a proline-arginine (PR) repeat peptide, and any combination thereof, or CD40, OX40, ICOS, CD28, CD137 / 4-1BB, CD27, GITR, PD-L1, CTLA4, PD-L2, PD-1, B7-H3, B7-H4, HVEM, LIGHT, BTLA, CD38 , TIGIT, VISTA, KIR, GAL9, TIM1, TIM3, TIM4, A2AR3, DR5, CD39, CD70, CD73, LAG3, TREM1, TREM2, Siglec-5, Siglec-7, Siglec-9, Siglec-11, SirpA, CD47, CSF1-receptor, phosphatidylserine, pathogenic nucleic acid, antisense GGCCCC (G2C4) repeat expanded RNA, and any combination thereof.
[0027] In some embodiments that may be combined with any of the preceding embodiments, the antibody has a dissociation constant (K) for human CD33 that is at least 1.8-fold lower than an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:4. D ) and K D is determined by BioLayer interferometry.
[0028] In some embodiments that may be combined with any of the preceding embodiments, the antibody has a dissociation constant (K) for human CD33 in the range of about 2 nM to about 200 pM, or less than about 200 pM. D ) and K D is determined by BioLayer interferometry.
[0029] In some embodiments that may be combined with any of the preceding embodiments, the antibody reduces cell surface levels of CD33. In some embodiments, CD33 is expressed on the surface of human dendritic cells. In some embodiments, the antibody reduces cell surface levels of CD33 in vitro. In some embodiments, the antibody has a median effective concentration (EC ) of less than 40 pM as measured by flow cytometry. 50 ) and reduces cell surface levels of CD33 in vitro.
[0030] In some embodiments that may be combined with any of the preceding embodiments, the antibody increases expression of one or more disease-associated microglia (DAM) markers. In some embodiments, the one or more DAM markers are ApoE3, Tyrobp, B2m, Trem2, Cst7, Ctsl, Lpl, Cd9, Axl, Csfl, Ccl6, Itgax, Clec7a, Lilrb4, Timp2, or any combination thereof.
[0031] In some embodiments that may be combined with any of the preceding embodiments, the antibody is selected from the group consisting of 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, The antibody or antibody composition competes for binding to human CD33 with one or more antibodies selected from the group consisting of: 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof.
[0032] In some embodiments that may be combined with any of the preceding embodiments, the antibody is selected from the group consisting of 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7 and 6C7H51, 6C7H52, 6C7H53, and 6C7H54.
[0033] In some embodiments that may be combined with any of the preceding embodiments, the antibody has an Fc region comprising the amino acid sequence of SEQ ID NO:118.
[0034] In some embodiments that may be combined with any of the preceding embodiments, an anti-CD33 antibody of the present disclosure comprises a heavy chain variable domain and a light chain variable domain, wherein (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 8, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 38, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 52, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; and (b) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 8; HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (c) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 9, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, and HVR-L2 comprises the amino acid sequence of SEQ ID NO: 54. and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (d) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 9, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (e) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 9, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39 (f) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 10, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (g) HVR-H1 comprises(h) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 12, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58. HVR-H1 comprises the amino acid sequence of SEQ ID NO: 14 and HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58, (i) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 13, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58, (j) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 14 and HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33 (k) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 15, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58. (l) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 16, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58, (m) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 17, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, and HVR-L1HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (n) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 18, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (o) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 19, and H HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (p)HVR-H1 comprises the amino acid sequence of SEQ ID NO: 20, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, and HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53 and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (q) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 21, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (r) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 22, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39 HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58, (s) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 23, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58, and (t) HVR-H1(u) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 25, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58. HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (v) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 26, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39; HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (w) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 27, and HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33. (x) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 28, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58. (y) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 29, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 59; (z) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 29, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, and HVR-L1HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 60, (aa) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 29, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 61, (bb) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 29, HV R-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 62, (cc) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 30, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 40, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, and HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, HVR-L3 comprises the amino acid sequence of SEQ ID NO: 59, (dd) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 30, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 40, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, HVR-L3 comprises the amino acid sequence of SEQ ID NO: 60, (ee) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 30, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 4 0, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 61, (ff) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 30, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 40, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 62, and (gg) HV R-H1 comprises the amino acid sequence of SEQ ID NO: 30, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 60; (hh)HVR-H1 comprises the amino acid sequence of SEQ ID NO: 30, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, and HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47 (i) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 23, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 60, (jj) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 23 and HVR-H2 comprisesHVR-H1 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 62; (kk) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 30, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 59; (ll) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 30, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, and HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47 HVR-H1 comprises the amino acid sequence of SEQ ID NO: 28, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 59, and (nn) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 28, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 61.
[0035] In some embodiments that may be combined with any of the preceding embodiments, an anti-CD33 antibody of the present disclosure comprises a light chain variable region comprising an amino acid sequence selected from any of SEQ ID NOs: 94-103, and / or a heavy chain variable domain comprising an amino acid sequence selected from any of SEQ ID NOs: 65-93. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 94, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 65. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 94, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 66. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 95, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 65. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 95, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 67. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 95, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 66. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 96, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 65. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:96, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:67. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:68. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:98, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:69. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:69. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:94, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:65. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:99, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:69.In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:70. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:71. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:72. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:73. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:74. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:75. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:76. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:77. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:78. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:79. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:80. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:81. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:82. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:83.In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:84. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:85. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:86. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:87. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:88. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:100, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:89. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:101, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:89. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 89. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 89. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 90. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 90. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 90. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 90. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 91.In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 91. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 91. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 91. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 92. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 92. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 93. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 93. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 83. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 83. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 92. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 92. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 93. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 93. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 83.In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:102 and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:83.
[0036] In another aspect, the disclosure pertains to an isolated nucleic acid comprising a nucleic acid sequence encoding any of the antibodies described herein.
[0037] In another aspect, the disclosure relates to a vector comprising any of the nucleic acids described herein. In some embodiments, the vector is an expression vector and / or a display vector.
[0038] In another aspect, the disclosure relates to an isolated host cell comprising any of the nucleic acids or vectors described herein.
[0039] In another aspect, the disclosure relates to a method of producing an antibody that binds to CD33, comprising culturing any of the host cells described herein to produce the antibody. In some embodiments, the method further comprises recovering the antibody produced by the cell.
[0040] In another aspect, the disclosure relates to an antibody produced by any of the methods described herein.
[0041] In another aspect, the present disclosure relates to a pharmaceutical composition comprising any of the antibodies described herein and a pharmaceutically acceptable carrier. In some embodiments, the present disclosure relates to the use of any of the antibodies described herein for the preparation of a medicament.
[0042] In another aspect, the present disclosure relates to a method of preventing, reducing the risk of, or treating a disease, disorder, or injury selected from the group consisting of dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, taupathies, infectious diseases, and cancer, comprising administering to an individual in need thereof a therapeutically effective amount of any of the antibodies described herein. In some embodiments, the disease, disorder, or injury is cancer. In some embodiments, the cancer is selected from the group consisting of bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), and multiple myeloma. In some embodiments, the disclosure relates to the use of any of the antibodies described herein for the preparation of a medicament useful for preventing, reducing the risk of, or treating a disease, disorder, or injury selected from the group consisting of dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, taupathies, infectious diseases, and cancer. In some embodiments, the disease, disorder, or injury is cancer. In some embodiments, the cancer is selected from the group consisting of bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), and multiple myeloma.
[0043] It should be understood that one, some, or all of the features of the various embodiments described herein may be combined to form other embodiments of the present invention. These and other aspects of the present invention will become apparent to those skilled in the art. These and other embodiments of the present invention are further described in the detailed description that follows. [Brief explanation of the drawings]
[0044] [Figure 1] Data are presented showing that the anti-CD33 antibodies of the present disclosure bind to primary human dendritic cells. [Figure 2] Data are presented showing that anti-CD33 antibodies of the present disclosure downregulate CD33 cell surface levels on human dendritic cells. [Figure 3] Data are presented showing that the anti-CD33 antibodies of the present disclosure bind to primary human dendritic cells. [Figure 4] Data are presented showing that the anti-CD33 antibodies of the disclosure bind to human CD33 and cynomolgus monkey (cyno) CD33 proteins. [Figure 5] Data are presented showing that the anti-CD33 antibodies of the present disclosure downregulate cell surface levels of CD33 on human dendritic cells. [Figure 6] Panels A and B present data showing that anti-CD33 antibodies of the present disclosure bind to recombinant human CD33. [Figure 7] Data are presented showing that the anti-CD33 antibodies of the present disclosure bind to primary human dendritic cells. [Figure 8] Panels A and B present data comparing the reduction of cell surface levels of CD33 on dendritic cells by various anti-CD33 antibodies of the present disclosure. [Figure 9] Data are presented showing that anti-CD33 antibody variants of the present disclosure bind to primary human dendritic cells. [Figure 10] Panels A and B present data showing that anti-CD33 antibody variants of the present disclosure bind to human CD33 and cynomolgus monkey CD33 proteins, respectively. [Figure 11] Data are presented showing that anti-CD33 antibody variants of the present disclosure reduce cell surface levels of CD33 in primary human dendritic cells. [Figure 12A] 1 presents data showing that anti-CD33 antibody variants, including Fc variants, reduce cell surface levels of CD33 on primary human dendritic cells. [Figure 12B]1 presents data showing that anti-CD33 antibody variants, including Fc variants, reduce cell surface levels of CD33 on primary human dendritic cells. [Figure 12C] 1 presents data showing that anti-CD33 antibody variants, including Fc variants, reduce cell surface levels of CD33 on primary human dendritic cells. DETAILED DESCRIPTION OF THE INVENTION
[0045] The present disclosure relates to anti-CD33 antibodies (e.g., monoclonal antibodies); methods of making and using such antibodies; pharmaceutical compositions comprising such antibodies; nucleic acids encoding such antibodies; and host cells comprising nucleic acids encoding such antibodies.
[0046] The techniques and procedures described or referenced herein are generally familiar to those skilled in the art and are commonly employed using conventional methodologies, e.g., widely used methodologies such as those described in Sambrook et al. Molecular Cloning: A Laboratory Manual 3rd edition (2001) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, Current Protocols in Molecular Biology (F.M.A. Usubel, et al. eds., (2003), Monoclonal Antibodies: A Practical Approach (P. Shepherd and C. Dean, eds., Oxford University Press, 2000).
[0047] I. Definition The terms "CD33" or "CD33 polypeptide," unless otherwise indicated, are used interchangeably herein and refer herein to any native CD33 from any vertebrate source, including mammals such as primates (e.g., humans and cynomolgus monkeys) and rodents (e.g., mice and rats). In some embodiments, the term encompasses both wild-type sequences and naturally occurring variant sequences, e.g., splice variants or allelic variants. In some embodiments, the term encompasses "full-length," unprocessed CD33, as well as any form of CD33 resulting from intracellular processing. In some embodiments, CD33 is human CD33 isoform 1 (NCBI Reference Sequence: NP_001763.3). In some embodiments, the amino acid sequence of an exemplary human CD33 is SEQ ID NO: 1. The amino acid sequence of cynomolgus monkey CD33 is SEQ ID NO: 2 (NCBI Reference Sequence: XP_005590138.1).
[0048] The terms "anti-CD33 antibody," "antibody that binds to CD33," and "antibody that specifically binds to CD33" refer to an antibody that can bind to CD33 with sufficient affinity such that the antibody is useful for targeting CD33 as a diagnostic and / or therapeutic agent. In one embodiment, the extent of binding of an anti-CD33 antibody to an unrelated, non-CD33 polypeptide is less than about 10% of the binding of the antibody to CD33, as measured, for example, by radioimmunoassay (RIA). In certain embodiments, an antibody that binds to CD33 has an affinity of <1 μM, <100 nM, <10 nM, <1 nM, <0.1 nM, <0.01 nM, or <0.001 nM (e.g., 10 -8 M or less, e.g. 10 -8 M~10 -13 M, e.g., 10 -9 M~10 -13 In certain embodiments, the anti-CD33 antibody binds to an epitope of CD33 that is conserved among CD33 from different species.
[0049] With respect to the binding of an antibody to a target molecule, the term "specific binding" to or "specifically binds to" or "specific for" a particular polypeptide or epitope on a particular polypeptide target refers to binding that is measurably different from non-specific interactions. Specific binding can be measured, for example, by determining the binding of a molecule relative to the binding of a control molecule. For example, specific binding can be determined by competition with a control molecule similar to the target, e.g., an excess of unlabeled target. In this case, specific binding is indicated when the binding of the labeled target to the probe is competitively inhibited by an excess of unlabeled target. The term "specific binding" to or "specifically binds to" or "specific for" a particular polypeptide or epitope on a particular polypeptide target, as used herein, refers to binding that is measurably different from non-specific interactions, for example, when the KD for the target is about 10 -4 M or less, 10 -5 M or less, 10 -6 M or less, 10 -7 M or less, 10 -8 M or less, 10 -9 M or less, 10 -10 M or less, 10 -11 M or less, 10 -12 M or less, or KD is 10 -4 M~10 -6 M or 10 -6 M~10 -10 M or 10 -7 M~10 -9 M. As will be appreciated by those skilled in the art, affinity and KD values are inversely related. High affinity for an antigen is measured by a low KD value. In one embodiment, the term "specific binding" refers to binding such that a molecule binds to a particular polypeptide or an epitope on a particular polypeptide without substantially binding to any other polypeptides or polypeptide epitopes.
[0050] The term "immunoglobulin" (Ig) is used interchangeably herein with "antibody." The term "antibody" is used herein in the broadest sense and specifically includes monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), such as those formed from at least two intact antibodies, and antibody fragments, so long as they exhibit the desired biological activity.
[0051] "Native antibodies" are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light ("L") chains and two identical heavy ("H") chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies among the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (V H ) followed by several constant domains. Each light chain has a variable domain (V L ) at its other end and a constant domain. The light-chain constant domain is aligned with the first constant domain of the heavy chain, and the light-chain variable domain is aligned with the heavy-chain variable domain. Particular amino acid residues are believed to form an interface between the light- and heavy-chain variable domains.
[0052] For the structure and properties of different classes of antibodies, see, e.g., Basic and Clinical Immunology, 8th Ed., Daniel P. Stites, Abba I. Terr and Tristram G. Parslow (eds.), Appleton & Lange, Norwalk, CT, 1994, page 71 and Chapter 6.
[0053] Light chains from any vertebrate species can be assigned to one of two clearly distinct types, called kappa ("κ") and lambda ("λ"), based on the amino acid sequence of their constant domains. Immunoglobulins can be assigned to different classes or isotypes depending on the amino acid sequence of the constant domain (CH) of their heavy chains. There are five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, with heavy chains designated alpha ("α"), delta ("δ"), epsilon ("ε"), gamma ("γ"), and mu ("μ"), respectively. The gamma and alpha classes are further divided into subclasses (isotypes) based on relatively minor differences in CH sequence and function; for example, humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known; see, e.g., Abbas et al., Cellular and Molecular Immunology, 4 th This is roughly described in Saunders Co., ed. (WBSaunders Co., 2000).
[0054] A "variable region" or "variable domain" of an antibody, such as an anti-CD33 antibody of this disclosure, refers to the amino-terminal domains of the heavy or light chain of the antibody. The variable domains of the heavy and light chains, respectively, are referred to as "V H " and "V L These domains are generally the most variable parts of an antibody (relative to other antibodies of the same class) and contain the antigen-binding sites.
[0055] The term "variable" refers to the fact that the sequences of certain segments of the variable domains vary considerably between antibodies, such as the anti-CD33 antibodies of the present disclosure. The variable domains mediate antigen binding and define the specificity of a particular antibody for a particular antigen. However, variability is not uniformly distributed throughout the variable domains. Rather, it is concentrated in three segments called hypervariable regions (HVRs) in both the light- and heavy-chain variable domains. The more highly conserved portions of the variable domains are called framework regions (FRs). Naturally occurring heavy- and light-chain variable domains each contain four FR regions, most of which are in a β-sheet configuration connected by three HVRs that form loops that connect, and in some cases form part of, the β-sheet configuration. The HVRs in each chain are held in close proximity and connected to each other by the FR regions, and together with the HVRs of the other chain, contribute to the formation of the antigen-binding site of the antibody (see Kabat et al., Sequences of Immunological Interest, Fifth Edition, National Institutes of Health, Bethesda, MD (1991)). The constant domains are not directly involved in binding the antibody to the antigen, but exhibit various effector functions, such as the participation of the antibody in antibody-dependent cellular toxicity.
[0056] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous antibody population, e.g., an anti-CD33 monoclonal antibody of the present disclosure. That is, the individual antibodies within the population are identical except for minor naturally occurring mutations and / or post-translational modifications (e.g., isomerization, amidation, etc.), which may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. In contrast to polyclonal antibody preparations, which typically contain different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, monoclonal antibodies are advantageous in that they are synthesized by hybridoma culture, uncontaminated by other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous antibody population and should not be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies for use in accordance with the present disclosure can be made by a variety of techniques, including, but not limited to, one or more of the following methods: immunization of animals, including, but not limited to, rats, mice, rabbits, guinea pigs, hamsters, and / or chickens, with one or more of DNA(s), virus-like particles, polypeptide(s), and / or cell(s); hybridoma methods; B-cell cloning methods; recombinant DNA methods; and techniques for generating human or human-like antibodies in animals that possess some or all of the human immunoglobulin loci or genes encoding human immunoglobulin sequences.
[0057] The terms "full-length antibody," "intact antibody," or "whole antibody" are used interchangeably and refer to an antibody, such as an anti-CD33 antibody of the present disclosure, in a substantially intact form, as opposed to an antibody fragment. Specifically, whole antibodies include those having heavy and light chains, including an Fc region. The constant domains may be native-sequence constant domains (e.g., human native-sequence constant domains) or amino acid sequence variants thereof. In some cases, an intact antibody may have one or more effector functions.
[0058] "Antibody fragment" refers to a molecule other than an intact antibody that contains a portion of the intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies (see U.S. Pat. No. 5,641,870, Example 2; Zapata et al., Protein Eng. 8(10):1057-1062 (1995)); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
[0059] Papain digestion of antibodies, such as the anti-CD33 antibodies of the present disclosure, produces two identical antigen-binding fragments called "Fab" fragments, and a residual "Fc" fragment, a designation reflecting its ease of crystallization. The Fab fragment contains the entire light chain plus the variable region domain (V) of the heavy chain. H ) and the first constant domain of one heavy chain (C H Each Fab fragment is monovalent with respect to antigen binding, i.e., it has a single antigen-binding site. Pepsin treatment of an antibody yields a single large F(ab')2 fragment. This fragment roughly corresponds to two disulfide-linked Fab fragments with different antigen-binding activities and is still capable of cross-linking antigen. The Fab' fragment is C H F(ab')2 antibody fragments differ from Fab fragments by having several additional residues at the carboxy terminus of one domain, including one or more cysteines from the antibody hinge region. Fab'-SH is the designation used herein for Fab' in which the cysteine residue(s) in the constant domains bear a free thiol group. F(ab')2 antibody fragments originally were produced as a pair of Fab' fragments with a hinge cysteine between them. Other chemical couplings of antibody fragments are also known.
[0060] The Fc fragment contains the carboxy-terminal portions of both heavy chains held together by disulfides. The effector functions of an antibody are determined by the sequence of the Fc region. This region is also recognized by Fc receptors (FcRs) found on certain cell types.
[0061] "Functional fragments" of antibodies, such as the anti-CD33 antibodies of the present disclosure, include portions of an intact antibody, generally including the antigen-binding or variable region of the intact antibody, or the Fc region of the antibody that retains or has modified FcR binding ability. Examples of antibody fragments include linear antibodies, single-chain antibody molecules, and multispecific antibodies formed from antibody fragments.
[0062] The term "diabody" refers to a short linker (approximately 5-10 residues) between the V H Domains and V L refers to small antibody fragments prepared by constructing an sFv fragment (see previous paragraph) such that the V of two antibodies is paired together to achieve interchain rather than intrachain pairing of the variable domains, thereby resulting in a bivalent fragment, i.e., a fragment with two antigen-binding sites. H Domain and V L It is a heterodimer of two "crossover" sFv fragments in which the domains are present on different polypeptide chains.
[0063] As used herein, "chimeric antibody" refers to antibodies (immunoglobulins), such as the chimeric anti-CD33 antibodies of the present disclosure, in which a portion of the heavy and / or light chain is identical to or homologous to corresponding sequences in antibodies from a particular species or belonging to a particular antibody class or subclass, and the remainder of the chain(s) is identical to or homologous to corresponding sequences in antibodies from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity. Chimeric antibodies of interest herein include PRIMATIZED® antibodies, the antigen-binding region of which is derived from an antibody generated, for example, by immunizing macaque monkeys with an antigen of interest. As used herein, "humanized antibody" is used as a subset of "chimeric antibody."
[0064] "Humanized" forms of non-human (e.g., murine) antibodies, such as humanized forms of the anti-CD33 antibodies of the present disclosure, are chimeric antibodies comprising amino acid residues from non-human HVRs and human FRs. In certain embodiments, a humanized antibody comprises substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization.
[0065] A "human antibody" is an antibody having an amino acid sequence corresponding to that of an antibody, such as the anti-CD33 antibody of the present disclosure, produced by a human and / or produced using any of the techniques for producing human antibodies disclosed herein. This definition of a human antibody specifically excludes humanized antibodies that contain non-human antigen-binding residues. Human antibodies can be produced using a variety of techniques known in the art, including phage display libraries and yeast display libraries. Human antibodies can be prepared by administering antigen to transgenic animals, e.g., immunized xenogeneic mice, that have been modified to produce such antibodies in response to antigen challenge but have disabled endogenous gene loci, or can be produced by human B-cell hybridoma technology.
[0066] As used herein, the terms "hypervariable region," "HVR," or "HV" refer to the regions of an antibody variable domain, such as those of an anti-CD33 antibody of the disclosure, that are hypervariable in sequence and / or form structurally defined loops. Generally, antibodies contain six HVRs, three of which are V H (H1, H2, H3), three are V LIn natural antibodies, H3 and L3 show the highest diversity among the six HVRs, and H3 in particular is thought to play a unique role in conferring superior specificity to antibodies. Naturally occurring camelid antibodies consisting only of heavy chains are functional and stable in the absence of light chains.
[0067] Several descriptions of HVRs are used herein and are encompassed herein. In some embodiments, HVRs may be complementarity-determining regions (CDRs) according to Kabat, which are based on sequence variability and are the most commonly used (Kabat et al., supra). In some embodiments, HVRs may be Chothia CDRs. Chothia is not related to sequence variability but rather to the location of structural loops (Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)). In some embodiments, HVRs may be AbM HVRs. AbM HVRs represent a compromise between Kabat CDRs and Chothia structural loops and are used by Oxford Molecular's AbM antibody modeling software. In some embodiments, HVRs may be "contact" HVRs. "Contact" HVRs are based on analysis of available complex crystal structures. The residues of each of these HVRs are shown below. TIFF0007586813000001.tif53170
[0068] HVRs may include the following "extended HVRs": 24-36 or 24-34 (L1), 46-56 or 50-56 (L2), and 89-97 or 89-96 (L3) in VL, and 26-35 (H1), 50-65 or 49-65 (preferred embodiment) (H2), and 93-102, 94-102, or 95-102 (H3) in VH. The variable domain residues are numbered according to Kabat et al. (supra) for each of these extended HVR definitions.
[0069] "Framework" or "FR" residues are those variable domain residues other than the HVR residues as herein defined.
[0070] As used herein, an "acceptor human framework" refers to a V-framework derived from a human immunoglobulin framework or a human consensus framework. L or V H A framework comprising the amino acid sequence of a framework. An acceptor human framework "derived" from a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence as the framework, or may comprise pre-existing amino acid sequence changes. In some embodiments, the number of pre-existing amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. When pre-existing amino acid changes are present in VH, preferred amino acid changes occur at only three, two, or one of positions 71H, 73H, and 78H; for example, the amino acid residues at these positions may be 71A, 73T, and / or 78A. In one embodiment, the sequence of the VL acceptor human framework is V L It is identical to a human immunoglobulin framework sequence or a human consensus framework sequence.
[0071] The "human consensus framework" is the V of human immunoglobulins. L Array or V H A framework representing the most commonly occurring amino acid residues in a framework sequence selection. Generally, the V of a human immunoglobulin L Array or V H The selection of sequences is made from a subgroup of variable domain sequences. Typically, the subgroup of sequences is a subgroup such as those found in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991). For example, V LIn the case of V, the subgroup can be subgroup kappa I, kappa II, kappa III, or kappa IV as in Kabat et al. (supra). H In this case, the subgroup can be subgroup I, subgroup II, or subgroup III as in Kabat et al., supra.
[0072] For example, an "amino acid modification" at a specific position in an anti-CD33 antibody of the present disclosure refers to a substitution or deletion of the specific residue, or an insertion of at least one amino acid residue adjacent to the specific residue. An insertion "adjacent to" a specific residue refers to an insertion within one to two residues of the specific residue. The insertion may be on the N-terminal or C-terminal side of the specific residue. A preferred amino acid modification herein is a substitution.
[0073] An "affinity matured" antibody, e.g., an affinity matured anti-CD33 antibody of the present disclosure, is an antibody that has one or more changes in one or more HVRs thereof such that the affinity of the antibody for the antigen is improved compared to a parent antibody that does not have those change(s). In one embodiment, the affinity matured antibody has nanomolar or even picomolar affinity for the target antigen. Affinity matured antibodies are generated by techniques known in the art. For example, Marks et al. Bio / Technology 10:779-783 (1992) describe V H Domains and V L Affinity maturation by domain shuffling and random mutagenesis of HVR and / or framework residues has been described, for example, in Barbas et al. Proc Nat. Acad. Sci. USA 91:3809-3813 (1994), Schier et al. Gene 169:147-155 (1995), Yelton et al. J. Immunol. 155:1994-2004 (1995), Jackson et al. J. Immunol. 154(7):3310-9 (1995), and Hawkins et al. J. Mol. Biol. 226:889-896 (1992).
[0074] An "Fv" is the minimum antibody fragment containing a complete antigen-recognition and antigen-binding site. This fragment consists of a dimer of one heavy-chain and one light-chain variable region domain in tight, non-covalent association. The folding of these two domains generates six hypervariable loops (three loops each from the H and L chains) that contribute amino acid residues for antigen binding and confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv containing only three antigen-specific HVRs) has the ability to recognize and bind antigen, albeit with lower affinity than the entire binding site.
[0075] A "single-chain Fv," also abbreviated as "sFv" or "scFv," is an antibody fragment comprising the VH and VL antibody domains joined into a single polypeptide chain. Preferably, the sFv polypeptide comprises a VH domain and a VL domain. H Domains and V L It further comprises a polypeptide linker between the domains that enables the sFv to form the desired structure for antigen binding.
[0076] Antibody "effector functions" refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody, and vary with the antibody isotype.
[0077] The term "Fc region" herein is used to define the C-terminal region of an immunoglobulin heavy chain, including native-sequence Fc regions and variant Fc regions. Although the boundaries of the Fc region of an immunoglobulin heavy chain can vary, the human IgG heavy chain Fc region is usually defined to stretch from the amino acid residue at position Cys226, or from Pro230, to the carboxyl terminus. The C-terminal lysine of the Fc region (residue 447 according to the EU numbering system) can be removed, for example, during antibody production or purification, or by recombinantly engineering the nucleic acid encoding the antibody heavy chain. Thus, an intact antibody composition can include an antibody population in which the entire K447 residue has been removed, an antibody population in which the K447 residue has not been removed, and an antibody population having a mixture of antibodies with and without the K447 residue. Native-sequence Fc regions suitable for use in the antibodies of the present disclosure include human IgG1, IgG2, IgG3, and IgG4.
[0078] A "native sequence Fc region" comprises an amino acid sequence identical to that of an Fc region found in nature. Native sequence human Fc regions include native sequence human IgG1 Fc regions (non-A and A allotypes), native sequence human IgG2 Fc regions, native sequence human IgG3 Fc regions, and native sequence human IgG4 Fc regions, as well as naturally occurring variants thereof.
[0079] A "variant Fc region" comprises an amino acid sequence that differs from that of a native-sequence Fc region by virtue of at least one amino acid modification, preferably one or more amino acid substitution(s). Preferably, the variant Fc region has at least one amino acid substitution, e.g., about one to about ten amino acid substitutions, preferably about one to about five amino acid substitutions, within the native-sequence Fc region or the Fc region of the parent polypeptide compared to the native-sequence Fc region or the Fc region of the parent polypeptide. A variant Fc region herein preferably has at least about 80% homology with the native-sequence Fc region and / or the Fc region of the parent polypeptide, most preferably at least about 90% homology thereto, and more preferably at least about 95% homology thereto.
[0080] "Fc receptor" or "FcR" refers to a receptor that binds to the Fc region of an antibody. A preferred FcR is a native-sequence human FcR. Further preferred FcRs are those that bind IgG antibodies (gamma receptors), including receptors of the FcRγI, FcγRII, and FcγRIII subclasses, including allelic variants and alternatively spliced forms of these receptors. FcγRII receptors include FcγRIIA (an "activating receptor") and FcγRIIB (an "inhibiting receptor"), which have similar amino acid sequences but differ primarily in their cytoplasmic domains. Activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif ("ITAM") in its cytoplasmic domain. Inhibiting receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibition motif ("ITIM") in its cytoplasmic domain. Other FcRs, including those yet to be identified, are encompassed by the term "FcR" herein. FcRs can also extend the serum half-life of antibodies.
[0081] As used herein, "percent (%) amino acid sequence identity" and "homology" with respect to a peptide, polypeptide, or antibody sequence refer to the percentage of amino acid residues in a candidate sequence that are identical to amino acid residues in a particular peptide or polypeptide sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, without considering any conservative substitutions as part of the sequence identity. Alignment for determining percent amino acid sequence identity can be achieved in a variety of ways within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or MEGALIGN™ (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms known in the art necessary to achieve maximal alignment over the full length of the sequences being compared.
[0082] The term "compete," when used in the context of antibodies competing for the same epitope (e.g., neutralizing antibodies), refers to competition between the antibodies as determined in an assay in which the antibody being tested prevents or inhibits (e.g., reduces) specific binding of a reference molecule (e.g., a ligand, or reference antibody) to a common antigen (e.g., CD33 or a fragment thereof). To determine whether an antibody competes with another antibody, numerous types of competitive binding assays can be used, such as solid-phase direct or indirect radioimmunoassays (RIA), solid-phase direct or indirect enzyme immunoassays (EIA), sandwich competition assays (see, e.g., Stahl et al., 1983, Methods in Enzymology 9:242-253), solid-phase direct biotin-avidin EIA (see, e.g., Kirkland et al., 1986, J. Immunol. 137:3614-3619), solid-phase direct label assays, solid-phase direct label sandwich assays (see, e.g., Harlow and Lane, 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Press), solid-phase direct label RIA using 1-125 label (see, e.g., Morel et al., 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Press), and the like. (see, e.g., Cheung, et al., 1988, Molec. Immunol. 25:7-15), solid-phase direct biotin-avidin EIA (see, e.g., Cheung, et al., 1990, Virology 176:546-552), and direct labeling RIA (Moldenhauer et al., 1990, Scand. J. Immunol. 32:77-82) can be used. Typically, such assays involve the use of purified antigen bound to a solid surface, or cells bearing either of these, an unlabeled test antibody, and a labeled reference antibody. Competitive inhibition is measured by determining the amount of label bound to the solid surface or cells in the presence of the test antibody. Typically, the test antibody is present in excess. Antibodies identified by competitive assays (competing antibodies) include antibodies that bind to the same epitope as the reference antibody and antibodies that bind to epitopes close enough to the epitope bound by the reference antibody to create steric hindrance.Further details regarding methods for determining competitive binding are provided herein. Typically, when a competing antibody is present in excess, it inhibits (e.g., reduces) specific binding of a reference antibody to a common antigen by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 97.5%, and / or about 100%.
[0083] As used herein, an "interaction" between a CD33 polypeptide and a second polypeptide includes, but is not limited to, protein-protein interactions, physical interactions, chemical interactions, bonds, covalent bonds, and ionic bonds. As used herein, an antibody "inhibits the interaction" between two polypeptides when the antibody disrupts, reduces, or completely eliminates the interaction between the two polypeptides. An antibody of the present disclosure "inhibits the interaction" between two polypeptides when it binds to one of the two polypeptides. In some embodiments, the interaction may be inhibited by at least about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 97.5%, and / or about 100%.
[0084] The term "epitope" includes any determinant capable of binding by an antibody. An epitope is the region of an antigen to which an antibody directed against that antigen binds, and, if the antigen is a polypeptide, includes specific amino acids that directly contact the antibody. In most cases, epitopes reside on polypeptides, but in some cases, they may reside on other types of molecules, such as nucleic acids. Epitopes may include chemically active surface groups of molecules, such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and may have specific three-dimensional structural features and / or specific charge characteristics. In general, antibodies specific for a particular target antigen will preferentially recognize epitopes on the target antigen in a complex mixture of polypeptides and / or macromolecules.
[0085] An "agonist" or "activating" antibody is an antibody that induces (eg, increases) one or more activities or functions of an antigen after the antibody binds to the antigen.
[0086] An "antagonist" or "blocking" or "inhibitory" antibody is one that reduces, inhibits, and / or eliminates (e.g., decreases) binding of an antigen to one or more ligands after the antibody has bound to the antigen and / or reduces, inhibits, and / or eliminates (e.g., decreases) one or more activities or functions of the antigen after the antibody has bound to the antigen. In some embodiments, an antagonist, or blocking, or inhibitory antibody substantially or completely inhibits binding of an antigen to one or more ligands and / or one or more activities or functions of the antigen.
[0087] An "isolated" antibody, e.g., an isolated anti-CD33 antibody of the present disclosure, is one that has been identified, separated, and / or recovered (e.g., naturally or recombinantly) from components of its production environment. Preferably, an isolated antibody is free of association with all other contaminating components from its production environment, such as those resulting from recombinantly transfected cells, which typically interfere with research, diagnostic, or therapeutic uses of the antibody and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the antibody is purified (1) to greater than 95% by weight, and in some embodiments greater than 99% by weight, as determined, e.g., by the Lowry method; (2) sufficiently to obtain at least 15 N-terminal or internal amino acid sequence residues using a spinning cup sequencer; or (3) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue staining or, preferably, silver staining. Isolated antibody includes the antibody in situ within recombinant T cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated polypeptide or antibody will be prepared by at least one purification step.
[0088] An "isolated" nucleic acid molecule encoding an antibody, such as an anti-CD33 antibody of the present disclosure, is a nucleic acid molecule that has been identified and separated from at least one contaminant nucleic acid molecule with which it is normally associated in the environment in which it is produced. Preferably, an isolated nucleic acid is free from association with all components associated with the production environment. Isolated nucleic acid molecules encoding the polypeptides and antibodies of the present disclosure are present in a form that is different from the form or setting in which they are found in nature. Thus, isolated nucleic acid molecules are distinguished from nucleic acids encoding the polypeptides and antibodies of the present disclosure that naturally occur in cells.
[0089] As used herein, the term "vector" is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid." A plasmid is a circular double-stranded DNA into which additional DNA segments can be ligated. Another type of vector is a phage vector. Another type of vector is a viral vector, in which additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operably linked. Such vectors are referred to herein as "recombinant expression vectors" or simply "expression vectors." In general, expression vectors utilized in recombinant DNA techniques are often in the form of plasmids. As used herein, "plasmid" and "vector" may be used interchangeably, as the plasmid is the most commonly used form of vector.
[0090] The terms "polynucleotide" and "nucleic acid" are used interchangeably herein and refer to a polymer of nucleotides of any length, including DNA and RNA. The nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and / or their analogs, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase or by a synthetic reaction.
[0091] A "host cell" includes an individual cell or cell culture that can be or has been the recipient of a vector(s) for incorporating a polynucleotide insert. A host cell includes the progeny of a single host cell, which progeny may not necessarily be completely identical (in morphology or in complementary strands of genomic DNA) to the original parent cell due to spontaneous, accidental, or deliberate mutation. A host cell includes cells transfected in vivo with a polynucleotide(s) of the present disclosure.
[0092] As used herein, a "carrier" includes a pharmaceutically acceptable carrier, excipient, or stabilizer that is non-toxic to cells or mammals exposed to the carrier at the dosages and concentrations employed.
[0093] As used herein, the term "preventing" includes providing prophylaxis against the occurrence or recurrence of a particular disease, disorder, or condition in an individual who may be predisposed or susceptible to a particular disease, disorder, or condition, or who may be at risk of developing such disease, disorder, or condition, but who has not yet been diagnosed with the disease, disorder, or condition.
[0094] As used herein, an individual "at risk" of developing a particular disease, disorder, or condition may or may not have detectable disease or disease symptoms, and may or may not exhibit detectable disease or disease symptoms prior to the treatment methods described herein. "At risk" means that an individual has one or more risk factors, which are measurable parameters known in the art that correlate with the development of a particular disease, disorder, or condition. Individuals with one or more of these risk factors are more likely to develop a particular disease, disorder, or condition than individuals without one or more of these risk factors.
[0095] As used herein, the term "treatment" refers to a clinical intervention designed to alter the natural course of a clinical pathology in a treated individual. Desirable effects of treatment include a reduction in the rate of progression of a particular disease, disorder, or condition, amelioration or alleviation of the pathological condition, and remission or improved prognosis. An individual is successfully "treated" if, for example, one or more symptoms associated with a particular disease, disorder, or condition are reduced or eliminated.
[0096] An "effective amount" refers to an amount effective, at least at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result. An effective amount may be provided in one or more administrations. The effective amount herein may vary depending on factors such as the individual's condition, age, sex, and weight, as well as the ability of the treatment to elicit a desired response in the individual. An effective amount is also one in which the therapeutically beneficial effects outweigh any toxic or detrimental effects of the treatment. For prophylactic use, beneficial or desired results include results such as elimination or reduction of the risk of disease, reduction in severity, or delay in the onset of disease (including biochemical, histological, and / or behavioral symptoms of the disease, its complications, and intermediate pathological phenotypes exhibited during the development of the disease). For therapeutic use, beneficial or desired results include clinical results such as attenuation of one or more symptoms attributable to the disease, improvement in the quality of life of an individual suffering from the disease, reduction in the dose of other drugs required to treat the disease, enhancement of the effectiveness of another drug, such as through targeting, delay in disease progression, and / or prolonged survival. An effective amount of a drug, compound or pharmaceutical composition is an amount sufficient to directly or indirectly perform preventive or therapeutic treatment.As understood in a clinical context, an effective amount of a drug, compound or pharmaceutical composition may or may not be achieved in combination with another drug, compound or pharmaceutical composition.Therefore, "effective amount" may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount when the desired result can or is achieved in combination with one or more other agents.
[0097] An "individual" for purposes of treatment, prevention, or risk reduction means any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sport, or pet animals, such as dogs, horses, rabbits, cows, pigs, hamsters, gerbils, mice, ferrets, rats, cats, etc. In some embodiments, the individual is a human.
[0098] As used herein, administration "in combination with" another compound or composition includes simultaneous administration and / or administration at different times. Co-administration also encompasses administration as a combined drug or as separate compositions, administration at different dosing frequencies or intervals, and administration using the same or different routes of administration. In some embodiments, co-administration is administration as part of the same therapeutic regimen.
[0099] As used herein, the term "about" refers to a normal error range for the respective value, which would be readily understood by one of ordinary skill in the art. Reference herein to a value or parameter with "about" includes (and describes) embodiments directed to that value or parameter itself.
[0100] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include the plural forms unless the context clearly dictates otherwise. For example, reference to an "antibody" is a reference to one antibody to multiple antibodies, such as molar amounts, and includes equivalents thereof known to those skilled in the art, and so forth.
[0101] It should be understood that aspects and embodiments of the present disclosure described herein include "comprising," "consisting of," and "consisting essentially of" aspects and embodiments.
[0102] Overview The present disclosure relates, in part, to anti-CD33 antibodies (including, e.g., antibodies that reduce cell surface levels of CD33 and / or bind to CD33 with improved / enhanced kinetics) that exhibit one or more improved and / or enhanced functional characteristics (e.g., compared to an anti-CD33 antibody having a heavy chain variable region comprising the sequence of SEQ ID NO: 3 and a light chain variable region comprising the sequence of SEQ ID NO: 4); methods of making and using such antibodies; pharmaceutical compositions comprising such antibodies; nucleic acids encoding such antibodies; and host cells comprising nucleic acids encoding such antibodies.
[0103] In some embodiments, anti-CD33 antibodies of the present disclosure have one or more activities attributable, at least in part, to the ability of the antibody to inhibit the interaction between CD33 and one or more natural glycan ligands. In some embodiments, anti-CD33 antibodies of the present disclosure may have one or more activities attributable, at least in part, to the ability of the antibody to reduce cellular expression (e.g., cell surface expression) of CD33 by inducing degradation, downregulation, cleavage, receptor desensitization, and / or lysosomal targeting of CD33. In some embodiments, anti-CD33 antibodies exhibit one or more of the following properties: a) a dissociation constant (K) for human CD33 that is lower than that of an anti-CD33 antibody having a heavy chain variable region comprising the sequence of SEQ ID NO:3 and a light chain variable region comprising the sequence of SEQ ID NO:4. D ), b) binds to human cells, such as primary human dendritic cells; c) has a lower median effective concentration (EC ) than that of an anti-CD33 antibody having a heavy chain variable region comprising the sequence of SEQ ID NO:3 and a light chain variable region comprising the sequence of SEQ ID NO:4. 50 ) to reduce the cell surface levels of CD33 (e.g., to reduce the cell surface levels of CD33 on primary human dendritic cells in vitro); d) to reduce, for example, the dissociation constant (K D ) for human CD33, which may range from about 0.061 nM to about 0.40 nM, as determined by surface plasmon resonance or BioLayer interferometry. D and / or e.g., median effective concentration (EC 50 ) as determined in vitro by flow cytometry, can range from about 78 pM to about 40 pM50 (e.g., reducing cell surface levels of CD33 on primary human dendritic cells in vitro). As disclosed herein, the half effective concentration (EC 50 ) means the concentration at which an anti-CD33 antibody of the disclosure reduces the cellular levels of CD33 on or within a cell to half that of untreated cells, or the concentration at which the antibody achieves half-maximal binding to CD33 on a cell.
[0104] Advantageously, the anti-CD33 antibodies of the present disclosure exhibit more potent (e.g., lower EC 50 (e.g., up to about 1.6-fold or up to 18-fold) reduction in cell surface expression of CD33 (see, e.g., Example 3). Additionally, advantageously, the anti-CD33 antibodies of the present disclosure exhibit higher affinity for CD33 (e.g., up to approximately 7-fold higher affinity) (e.g., lower K as measured by surface plasmon resonance) compared to a control anti-CD33 antibody (e.g., a control anti-CD33 antibody having a heavy chain variable region comprising the sequence of SEQ ID NO: 3 and a light chain variable region comprising the sequence of SEQ ID NO: 4). D Surprisingly, increased affinity for CD33 does not necessarily correlate with increased potency or efficacy in reducing cell surface expression of CD33.
[0105] Certain aspects of the present disclosure relate, at least in part, to reducing cell surface levels of CD33 on cells and inhibiting one or more CD33 activities (e.g., but not limited to, reducing cell proliferation of monocytes, macrophages, T cells, dendritic cells, and / or microglia; T proliferation induced by dendritic cells, bone marrow-derived dendritic cells, monocytes, microglia, M1 microglia, activated M1 microglia, M2 microglia, macrophages, M1 macrophages, activated M1 macrophages, and / or M2 macrophages). Decreased cell proliferation; decreased viability of neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, helper T cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia, and / or M2 microglia ... Decreased proliferation of helper T cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia, and / or M2 microglia; Inhibition of migration of neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, helper T cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia, and / or M2 microglia; Neutrophils, dendritic cells, bone marrow-derived Decreased function of one or more of dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, helper T cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia, and / or M2 microglia; reduced proliferation of monocytes, macrophages, T cells, dendritic cells, neutrophils, and / or microglia; reduced overall functionality of monocytes, macrophages, T cells, dendritic cells, neutrophils, and / or microglia;Inhibition of beneficial immune responses against different types of cancer selected from bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, acute myeloid leukemia, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma, and thyroid cancer; dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, amyotrophic lateral sclerosis, Huntington's disease, taupathies, Nasu-Hakola disease, stroke, acute trauma, chronic trauma, essential tremor, Behcet's disease, Parkinson's disease, Inhibition of beneficial immune responses to different types of neurological disorders selected from dementia with Lewy bodies, multiple system atrophy, Shy-Drager syndrome, progressive supranuclear palsy, corticobasal ganglionic degeneration, acute disseminated encephalomyelitis, granulomatous disease, sarcoidosis, geriatric diseases, convulsions, spinal cord injury, traumatic brain injury, age-related macular degeneration, glaucoma, retinitis pigmentosa, retinal degeneration, and multiple sclerosis; binding to CD33 ligand on tumor cells; binding to CD33 ligand on dendritic cells, bone marrow-derived dendritic cells, monocytes, microglia, T cells, neutrophils, and / or macrophages; microglia , macrophages, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, helper T cells, or cytotoxic T cells; inhibition of tumor cell killing by one or more of microglia, macrophages, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, helper T cells, or cytotoxic T cells; inhibition of anti-tumor cell proliferation activity by one or more of microglia, macrophages, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, helper T cells, or cytotoxic T cells; inhibition of anti-tumor cell metastasis activity by one or more of microglia, macrophages, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, helper T cells, or cytotoxic T cells; Modulation of the expression of one or more inflammatory receptors, such as CD86, expressed on one or more of myeloid-derived dendritic cells, neutrophils, T cells, helper T cells, or cytotoxic T cells; enhancement of the infiltration of one or more of immunosuppressive dendritic cells, immunosuppressive macrophages, myeloid-derived suppressor cells, tumor-associated macrophages, immunosuppressive neutrophils, and regulatory T cells into tumors; an increase in the number of tumor-promoting myeloid / granulocytic immunosuppressive cells in tumors, peripheral blood, or other lymphoid organs; an increase in the tumor-promoting activity of myeloid-derived suppressor cells; a decrease in the activation of tumor-specific T lymphocytes with tumor-killing potential;a decrease in the infiltration of tumor-specific T lymphocytes capable of killing tumors; an increase in the rate of tumor growth; an increase in the rate of tumor recurrence; one or more immunotherapies that modulate anti-tumor T cell responses (optionally, the one or more immunotherapies are selected from the group consisting of CD40, OX40, ICOS, CD28, CD137 / 4-1BB, CD27, GITR, PD-L1, CTLA4, PD-L2, PD-1, B7-H3, B7-H4, HVEM, LIGHT, BTLA, VISTA, KIR, GAL9, TIM1, TIM3, TIM4, A2AR, LAG3, DR-5, CD39, CD70, TREM1, TREM2, Siglec-5, Si and / or a reduced efficacy of one or more chemotherapeutic agents and / or cancer vaccines), including immunotherapy targeting one or more proteins selected from the group consisting of glec-7, Siglec-9, Siglec-11, SirpA, CD447, CSF-1 receptor, and any combination thereof; or a reduced efficacy of one or more chemotherapeutic agents and / or cancer vaccines;
[0106] In some embodiments, the treatment of cancer with the anti-CD33 antibodies described herein involves determining whether (i) tumor-infiltrating CD3 + (ii) expansion of T cell numbers; and (ii) non-tumorigenic CD14 + Decreased cellular levels of CD33 in bone marrow cells (possibly in combination with non-tumorigenic CD14 + The myeloid cells may be tumor-infiltrating cells or, optionally, non-tumorigenic CD14 + myeloid cells present in the blood); (iii) non-tumorigenic CD14 + Decreased numbers of myeloid cells (possibly non-tumorigenic CD14 + The myeloid cells may be tumor-infiltrating cells or, optionally, non-tumorigenic CD14 +(iv) a decrease in PD-L1, PD-L2, B7-H7, B7-H3, CD200R, CD163, and / or CD206 levels in one or more cells (optionally, one or more cells are non-tumorigenic myeloid-derived suppressor cells (MDSCs)); (v) a decrease in tumor growth rate of a solid tumor; (vi) a decrease in tumor volume; (vii) an increase in the efficacy of one or more PD-1 inhibitors; (viii) an increase in the efficacy of one or more checkpoint inhibitory therapies and / or immunomodulatory therapies (optionally, the one or more checkpoint inhibitory therapies and / or immunomodulatory therapies target one or more of CTL4, the adenosine pathway, PD-L1, PD-L2, OX40, TIM3, LAG3, or any combination thereof); (ix) an increase in the efficacy of one or more chemotherapeutic agents (optionally, one or more of the chemotherapeutic agents is gemcitabine, capexi (x) increasing T cell proliferation in the presence of non-tumorigenic myeloid-derived suppressor cells (MDSCs); (xi) inhibiting the differentiation, survival, and / or one or more functions of non-tumorigenic myeloid-derived suppressor cells (MDSCs); and (xii) killing CD33-expressing immunosuppressive non-tumorigenic myeloid cells and / or non-tumorigenic CD14-expressing cells in solid tumors and associated vasculature when conjugated to a chemical or radiotoxin.
[0107] In some embodiments, bone marrow cells of the present disclosure include, but are not limited to, CD45+CD14+ bone marrow cells, CD14+ bone marrow cells, and myeloid-derived suppressor cells (MDSCs). In some embodiments, bone marrow cells of the present disclosure are non-tumorigenic bone marrow cells. Immunosuppressive cells may also be referred to as myeloid-derived suppressor cells (MDSCs). In humans, MDSCs may be defined by one of the following marker combinations: (1) CD14+HLA-DRlow / -, (2) CD14+IL4Rα+, (3) CD14+HLA-DR-IL4Rα+, (4) CD34+CD14+CD11b+CD33+, (5) CD11b+CD14+CD33+, (6) CD33+HLA-DR-, (7) Lin-HLA-DR-, (8) Lin-HLA-DR-CD33+, (9) Lin-HLA- DR-CD33+CD11b+, (10)Lin-CD33+CD11b+CD15+, (11)Lin-HLA-DR-CD33+CD11b+CD14-CD15+, (12)CD11b+CD14-CD33+, (13)C D11b+CD14-HLA-DR-CD33+CD15+, (14)CD33+HLA-DR-CD15+, (15)CD15+IL4Rα+, (16)CD11b+CD15+CD66b+, (17)CD15+FSClow SSChigh, (18) CD15high CD33+, (19) CD11b+ CD14- CD15+, (20) CD66b+ SSChigh, and (21) CD11b+ CD15+ (see also Solito S et al. Annals of the NY Academy of Sciences, 2014). In mice, MDSCs can be defined by the expression of surface markers CD45+, CD11b+, Gr1+, and / or Il4Ra+. Further exemplary immunosuppressive monocyte lineages are CD45+, CD11b+, Gr1low; and CD45+, CD11c+.
[0108] CD33 protein In one aspect, the present disclosure provides antibodies, such as isolated (e.g., monoclonal) antibodies, that interact with or otherwise bind to a region, such as an epitope, within a CD33 protein of the disclosure. In some embodiments, the antibodies interact with or otherwise bind to a region, such as an epitope, within a CD33 protein of the disclosure with improved / enhanced kinetics (e.g., compared to an anti-CD33 antibody having a heavy chain variable region comprising the sequence of SEQ ID NO: 3 and a light chain variable region comprising the sequence of SEQ ID NO: 4). In some embodiments, the antibodies have a lower median effective concentration (EC ) than that of a control antibody (e.g., compared to an anti-CD33 antibody having a heavy chain variable region comprising the sequence of SEQ ID NO: 3 and a light chain variable region comprising the sequence of SEQ ID NO: 4). 50 ), which interacts with or otherwise binds to a region, such as an epitope, within the CD33 protein on a human cell, such as a dendritic cell. In some embodiments, an anti-CD33 antibody of the present disclosure binds to a CD33 protein and, after binding to the CD33 protein, modulates one or more CD33 activities, e.g., activities associated with CD33 expression on a cell. Thus, as used herein, a CD33 protein of the present disclosure includes, but is not limited to, a mammalian CD33 protein, a human CD33 protein, a mouse CD33 protein, and a rat CD33 protein.
[0109] CD33 is variously called CD33 molecule, Siglec3, Siglec-3, CD33 antigen (Gp67), P67, Gp67, sialic acid-binding Ig-like lectin 3, myeloid cell surface antigen CD33, or FLJ00391.
[0110] CD33 is an immunoglobulin-like receptor that is primarily expressed on myeloid cells, including, but not limited to, macrophages, dendritic cells, osteoclasts, monocytes, and microglia. In some embodiments, CD33 forms a receptor signaling complex with CD64. In some embodiments, CD33 signaling leads to downstream inhibition of PI3K or other intracellular signals. In myeloid cells, Toll-like receptor (TLR) signaling is important for inhibiting CD33 activity, for example, in the context of an infection response. TLRs, such as those expressed on macrophages and dendritic cells, also play an important role in pathological inflammatory responses.
[0111] TIFF0007586813000002.tif48170
[0112] TIFF0007586813000003.tif49170
[0113] In some embodiments, CD33 is a preprotein that includes a signal sequence. In some embodiments, CD33 is a mature protein. In some embodiments, the mature CD33 protein does not include a signal sequence. In some embodiments, the mature CD33 protein is expressed on a cell. In some embodiments, the mature CD33 protein is expressed on the surface of a cell, for example, on a cell, including, but not limited to, human dendritic cells, human macrophages, human monocytes, human osteoclasts, human neutrophils, human T cells, human helper T cells, human cytotoxic T cells, human granulocytes, and human microglia. The anti-CD33 antibodies of the present disclosure can bind to any of the CD33 proteins of the present disclosure expressed on any cell disclosed herein.
[0114] The CD33 proteins of the present disclosure, such as human CD33, comprise several domains, including, but not limited to, a signal sequence located at amino acid residues 1-17 of SEQ ID NO: 1, an extracellular immunoglobulin-like variable (IgV) domain located at amino acid residues 19-135 of SEQ ID NO: 1, an Ig-like C2-type domain located at amino acid residues 145-228 of SEQ ID NO: 1, a transmembrane domain located at amino acid residues 260-282 of SEQ ID NO: 1, ITIM motif 1 located at amino acid residues 338-343 of SEQ ID NO: 1, and ITIM motif 2 located at amino acid residues 356-361 of SEQ ID NO: 1. As will be understood by one of skill in the art, the starting and ending residues of the domains of the present disclosure may vary depending on the computer modeling program or method used to determine the domains.
[0115] Certain aspects of the present disclosure provide anti-CD33 antibodies that bind to human CD33 or homologs thereof, including, but not limited to, mammalian CD33 proteins and CD33 orthologs from other species. In some embodiments, the anti-CD33 antibodies of the present disclosure bind to human CD33 or homologs thereof with improved activity, such as improved / enhanced binding kinetics and / or reduced cellular levels of CD33 (e.g., compared to an anti-CD33 antibody having a heavy chain variable region comprising the sequence of SEQ ID NO: 3 and a light chain variable region comprising the sequence of SEQ ID NO: 4).
[0116] Thus, as used herein, "CD33" proteins of the present disclosure include, but are not limited to, mammalian CD33 proteins, human CD33 proteins, primate CD33 proteins, mouse CD33 proteins, and rat CD33 proteins. Furthermore, anti-CD33 antibodies of the present disclosure may bind to epitopes within human CD33 proteins and primate CD33. In some embodiments, anti-CD33 antibodies of the present disclosure may specifically bind to human CD33. In some embodiments, anti-CD33 antibodies of the present disclosure may bind to cynomolgus monkey CD33. In some embodiments, anti-CD33 antibodies of the present disclosure may bind to human CD33 and cynomolgus monkey CD33.
[0117] In some embodiments, antibodies of the present disclosure can bind to CD33 in a pH-dependent manner. In some embodiments, antibodies of the present disclosure can bind to CD33 at neutral pH and be internalized without dissociating from the CD33 protein. Alternatively, at acidic pH, antibodies of the present disclosure dissociate from CD33 after internalization and are then degraded via the endosomal / lysosomal pathway. In certain embodiments, anti-CD33 antibodies bind to CD33 at pHs ranging from 5.5 to 8.0, 5.5 to 7.5, 5.5 to 7.0, 5.5 to 6.5, 5.5 to 6.0, 6.0 to 8.0, 6.5 to 8.0, 7.0 to 8.0, 7.5 to 8.0, 6.0 to 7.5, 6.0 to 7.0, or 6.5 to 7.5. In certain embodiments, the anti-CD33 antibody dissociates from CD33 at a pH below 6.0, below 5.5, below 5.0, below 4.5, below 4.0, below 3.5, below 3.0, below 2.5, or below 2.0.
[0118] In some embodiments, the antibodies of the present disclosure bind to a wild-type CD33 protein of the present disclosure, a naturally occurring variant thereof, and / or a disease variant thereof.
[0119] In some embodiments, antibodies of the disclosure bind to a variant of human CD33, which variant comprises the single nucleotide polymorphism (SNP) rs3865444C at nucleotide (C). In some embodiments, antibodies of the disclosure that reduce cellular levels of CD33 and / or bind to or interact with CD33 bind to a variant of human CD33, which variant comprises the SNP rs3865444 at nucleotide (A). In some embodiments, anti-CD33 antibodies of the disclosure bind to a variant of human CD33, which variant comprises the SNP rs3865444 AC or rs3865444 CC Includes:
[0120] In some embodiments, antibodies of the disclosure that reduce cellular levels of CD33 and / or bind to or interact with CD33 bind to a variant of human CD33, which variant comprises SNP rs35112940 at a GG, AA, or AG nucleotide. In some embodiments, antibodies of the disclosure that reduce cellular levels of CD33 and / or bind to or interact with CD33 bind to a variant of human CD33, which variant comprises SNP rs12459419 at a CC, CT, or TT genotype. In certain embodiments, the subject is homozygous or heterozygous for the coding SNP rs1803 at a GG, CG, or CC nucleotide.
[0121] In some embodiments, antibodies of the present disclosure that reduce cellular levels of CD33 and / or bind to or interact with CD33 bind to CD33 protein expressed on the surface of cells, including, but not limited to, human dendritic cells, human macrophages, human monocytes, human osteoclasts, human neutrophils, human T cells, human helper T cells, human cytotoxic T cells, human granulocytes, and human microglia. In some embodiments, antibodies of the present disclosure that reduce cellular levels of CD33 and / or bind to or interact with CD33 bind to CD33 protein expressed on the cell surface and, after binding to the surface-expressed CD33 protein, modulate (e.g., induce or inhibit) at least one CD33 activity of the present disclosure. In some embodiments of the present disclosure, the anti-CD33 antibody specifically binds to CD33 protein. In some embodiments of the present disclosure, the anti-CD33 antibody further binds to at least one additional Siglec protein. In some embodiments, the anti-CD33 antibody modulates one or more activities of at least one additional Siglec protein or one or more activities of a cell expressing at least one additional Siglec protein.
[0122] CD33 Ligand The CD33 proteins of the present disclosure can interact with (eg, bind to) one or more CD33 ligands.
[0123] Exemplary CD33 ligands include, but are not limited to, sialic acid, sialic acid-containing glycolipids, sialic acid-containing glycoproteins, α-2,6-linked sialic acid-containing glycolipids, α-2,6-linked sialic acid-containing glycoproteins, α-2,3-linked sialic acid-containing glycolipids, α-2,3-linked sialic acid-containing glycoproteins, α-1-acid glycoprotein (AGP), CD24 protein, gangliosides (e.g., glycolipids containing ceramide attached to a sialylated glycan), secreted mucins, and erythrocyte-expressed sialic acid-containing glycolipids. CD33 ligand, CD33 ligand expressed on bacterial cells, CD33 ligand expressed on apoptotic cells, CD33 ligand expressed on tumor cells, CD33 ligand expressed on viruses, CD33 ligand expressed on dendritic cells, CD33 ligand expressed on neurons, CD33 ligand expressed on glial cells, CD33 ligand expressed on microglia, CD33 ligand expressed on astrocytes, CD33 ligand on beta-amyloid plaques, tau tangles (Tau Examples of CD33 ligands include CD33 ligands on inflammatory cytokines (e.g., tangles), CD33 ligands on pathogenic proteins, CD33 ligands on pathogenic peptides, CD33 ligands expressed on macrophages, CD33 ligands expressed on natural killer cells, CD33 ligands expressed on T cells, CD33 ligands expressed on helper T cells, CD33 ligands expressed on cytotoxic T cells, CD33 ligands expressed on B cells, CD33 ligands expressed on tumor-buried immunosuppressive dendritic cells, CD33 ligands expressed on tumor-buried immunosuppressive macrophages, CD33 ligands expressed on myeloid-derived suppressor cells, and CD33 ligands expressed on regulatory T cells. In some embodiments, the CD33 ligands of the present disclosure are gangliosides. Gangliosides generally share a common lacto-ceramide core and one or more sialic acid residues.
[0124] Further examples of suitable ganglioside ligands are listed in Table A. Generally, gangliosides are molecules composed of glycosphingolipids with one or more sialic acids (e.g., n-acetyl-neuraminic acid, NANA) attached to the sugar chain. TIFF0007586813000004.tif233170
[0125] Anti-CD33 antibody Certain aspects of the present disclosure relate to anti-CD33 antibodies comprising one or more improved and / or enhanced functional characteristics. In some embodiments, the anti-CD33 antibodies of the present disclosure comprise one or more improved and / or enhanced functional characteristics compared to a reference or control antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4). In some embodiments, the anti-CD33 antibodies of the present disclosure have a higher affinity for CD33 (e.g., human CD33) than that of the reference or control anti-CD33 antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4). In some embodiments, the anti-CD33 antibodies of the present disclosure have a lower half effective concentration (EC ) than that of the reference or control antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4). 50 In some embodiments, the anti-CD33 antibodies of the present disclosure bind to human cells, such as human primary dendritic cells, at a lower median effective concentration (EC ) than that of a reference or control antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the sequence of SEQ ID NO: 3 and a light chain variable region comprising the sequence of SEQ ID NO: 4). 50 ) to reduce cellular levels of CD33 (e.g., reduce or lower cell surface levels).
[0126] Cellular levels of CD33 can refer to, but are not limited to, cell surface levels of CD33, intracellular levels of CD33, and total levels of CD33. In some embodiments, reducing cellular levels of CD33 includes reducing cell surface levels of CD33. In some embodiments, anti-CD33 antibodies of the present disclosure that reduce cellular levels of CD33 (e.g., cell surface levels of CD33) have one or more of the following properties: (1) inhibiting or reducing one or more CD33 activities; (2) the ability to inhibit or reduce binding of CD33 to one or more of its ligands; (3) the ability to reduce CD33 expression in CD33-expressing cells; (4) the ability to interact with, bind to, or recognize CD33 protein; (5) the ability to specifically interact with or bind to CD33 protein; and (6) the ability to treat, ameliorate, or prevent any aspect of a disease or disorder described or contemplated herein.
[0127] The anti-CD33 antibodies of the present disclosure may have nanomolar or even picomolar affinities for the target antigen (e.g., human CD33). In certain embodiments, the dissociation constant (K D ) is about 0.001 to about 100 nM. In certain embodiments, the K D In certain embodiments, the K D In some embodiments, the K of the antibody is about 0.23 to about 3.88 nM. D is about 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 9.5 nM, 9 nM, 8.5 nM, 8 nM, 7.5 nM, 7 nM, 6.5 nM, 6 nM, 5.5 nM, 5 nM, 4.5 nM, 4 nM, 3.5 nM, 3 nM, 2.5 nM, 2 nM, 1.5 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.1 nM, 0.05 nM, 0.01 nM, or 0.005 nM or less. D In some embodiments, the K of the antibody is less than about 0.40 nM. DIn some embodiments, the K of the antibody is less than about 0.30 nM. D In some embodiments, the KD is less than about 0.20 nM. In some embodiments, the KD of the antibody is less than about 0.10 nM. D In some embodiments, the K of the antibody is about 0.061 nM. D is about 0.001 nM, 0.005 nM, 0.01 nM, 0.05 nM, 0.1 nM, 0.2 nM, 0.3 nM, 0.4 nM, 0.5 nM, 0.6 nM, 0.7 nM, 0.8 nM, 0.9 nM, 1 nM, 1.5 nM, 2 nM, 2.5 nM, 3 nM, 3.5 nM, 4 nM, 4.5 nM, 5 nM, 5.5 nM, 6 nM, 6.5 nM, 7 nM, 7.5 nM, 8 nM, 8.5 nM, 9 nM, 9.5 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, or 90 nM or more. D is an upper limit of about 100nM, 90nM, 80nM, 70nM, 60nM, 50nM, 40nM, 30nM, 20nM, 10nM, 9.5nM, 9nM, 8.5nM, 8nM, 7.5nM, 7nM, 6.5nM, 6nM, 5.5nM, 5nM, 4.5nM, 4nM, 3.5nM, 3nM, 2.5nM, 2nM, 1.5nM, 1nM, 0.9nM, 0.8nM, 0.7nM, 0.6nM, 0.5nM, 0.4nM, 0.3nM, 0.2nM, 0.1nM, 0.05nM, 0.01nM, or 0.005nM, and an upper limit of about 0.001nM, 0.005nM, 0.01nM, In some embodiments, the K of an antibody can be any of a range of affinities having an independently selected lower limit of 0.05 nM, 0.1 nM, 0.2 nM, 0.3 nM, 0.4 nM, 0.5 nM, 0.6 nM, 0.7 nM, 0.8 nM, 0.9 nM, 1 nM, 1.5 nM, 2 nM, 2.5 nM, 3 nM, 3.5 nM, 4 nM, 4.5 nM, 5 nM, 5.5 nM, 6 nM, 6.5 nM, 7 nM, 7.5 nM, 8 nM, 8.5 nM, 9 nM, 9.5 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, or 90 nM, where the lower limit is less than the upper limit. Dis about 10 nM, about 9 nM, about 8 nM, about 7 nM, about 6 nM, about 5 nM, about 4 nM, about 3 nM, about 2 nM, about 1 nM, about 900 pM, about 800 pM, about 700 pM, about 600 pM, about 500 pM, about 400 pM, about 300 pM, about 200 pM, or about 100 pM. Various methods of measuring antibody affinity are known in the art, including, for example, using surface plasmon resonance or BioLayer interferometry (see, e.g., Example 3 below). In some embodiments, the K for CD33 is D is determined at a temperature of approximately 25° C. In some embodiments, the K D is determined at a temperature of approximately 4°C. D is determined using a monovalent antibody (e.g., Fab) or a monovalent form of the full-length antibody. In some embodiments, K D is determined using bivalent antibodies and monomeric recombinant CD33 protein.
[0128] In some embodiments, an anti-CD33 antibody of the present disclosure has a lower dissociation constant (K) for CD33 than a reference anti-CD33 antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4). D In some embodiments, an anti-CD33 antibody of the present disclosure has a K that is less than or equal to that of a reference anti-CD33 antibody for a target (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4). D K for a target (e.g., human CD33) that is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% lower than DIn some embodiments, an anti-CD33 antibody of the present disclosure has a K of a reference anti-CD33 antibody for a target (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4). D the K for the target (e.g., human CD33) is at least about 1-fold, at least about 1.1-fold, at least about 1.5-fold, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 12.5-fold, at least about 15-fold, at least about 17.5-fold, at least about 20-fold, at least about 22.5-fold, at least about 25-fold, at least about 27.5-fold, at least about 30-fold, at least about 50-fold, or at least about 100-fold lower than D In some embodiments, an anti-CD33 antibody of the present disclosure has a K for human CD33 that is at least 7-fold higher than an anti-CD33 antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4. D In some embodiments, an anti-CD33 antibody of the present disclosure has a K for human CD33 that is at least 1.8-fold higher than an anti-CD33 antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4. D In some embodiments, affinity is measured by surface plasmon resonance. In some embodiments, affinity is measured at a temperature of approximately 25° C. In some embodiments, affinity is measured at a temperature of approximately 4° C. In some embodiments, affinity is measured using an experimental approach such as that described in the Examples below.
[0129] The anti-CD33 antibodies of the present disclosure have median effective concentrations (EC 50 ) (e.g., as measured in vitro using primary human dendritic cells). In certain embodiments, the EC 50In certain embodiments, the EC 50 In certain embodiments, the EC 50 In certain embodiments, the EC of the antibody is about 27 pM to about 40 pM. 50 In some embodiments, the EC of the antibody is about 78 pM to about 40 pM. 50 is about 500 pM, 400 pM, 300 pM, 250 pM, 225 pM, 200 pM, 175 pM, 150 pM, 125 pM, 100 pM, 75 pM, 50 pM, 25 pM, 10 pM, 1 pM, or 0.5 pM or less. 50 In some embodiments, the EC50 of the antibody is less than about 74.3 pM. 50 is about 0.1 pM, 0.5 pM, 1 pM, 10 pM, 25 pM, 50 pM, 75 pM, 100 pM, 125 pM, 150 pM, 175 pM, 200 pM, 225 pM, 250 pM, 300 pM, or 400 pM or more. 50 can be any of a range having an upper limit of about 500 pM, 400 pM, 300 pM, 250 pM, 225 pM, 200 pM, 175 pM, 150 pM, 125 pM, 100 pM, 75 pM, 50 pM, 25 pM, 10 pM, 1 pM, or 0.5 pM and an independently selected lower limit of about 0.1 pM, 0.5 pM, 1 pM, 10 pM, 25 pM, 50 pM, 75 pM, 100 pM, 125 pM, 150 pM, 175 pM, 200 pM, 225 pM, 250 pM, 300 pM, or 400 pM, wherein the lower limit is less than the upper limit. 50is approximately 1pM, 2pM, 3pM, 4pM, 5pM, 6pM, 7pM, 8pM, 9pM, 10pM, 15pM, 20pM, 25pM, 30pM, 35pM, 40pM, 45pM, 50pM, 55pM, 60pM, 65pM, 70pM, 75pM, 80pM, 85pM, 90pM, 95pM, 100p EC50 of the antibody is 100 pM, 105 pM, 110 pM, 115 pM, 120 pM, 125 pM, 130 pM, 135 pM, 140 pM, 145 pM, 150 pM, 155 pM, 160 pM, 165 pM, 170 pM, 175 pM, 180 pM, 185 pM, 190 pM, 195 pM, or 200 pM. 50 Various methods of measuring EC values are known in the art, including, for example, by flow cytometry (see, e.g., Example 3 below). 50 is measured in vitro using primary human dendritic cells. In some embodiments, EC 50 is measured in vitro using primary human monocytes. In some embodiments, EC 50 is measured in vitro using primary human macrophages. In some embodiments, EC 50 is measured in vitro using cultured cells transfected with human CD33. In some embodiments, EC 50 is measured at a temperature of approximately 4° C. In some embodiments, EC 50 is measured at a temperature of approximately 25° C. In some embodiments, EC 50 is measured at a temperature of approximately 35° C. In some embodiments, EC 50 is measured at a temperature of approximately 37° C. In some embodiments, EC 50 is determined using a monovalent antibody (e.g., Fab) or a monovalent form of the full-length antibody. In some embodiments, EC 50 is determined using an antibody comprising a constant region that exhibits increased Fc receptor binding. In some embodiments, EC 50 is determined using an antibody that contains a constant region that exhibits reduced Fc receptor binding.
[0130] In some embodiments, an anti-CD33 antibody of the present disclosure has a lower EC than a reference anti-CD33 antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4). 50 In some embodiments, an anti-CD33 antibody of the present disclosure reduces the cellular levels (e.g., reduces or lowers cell surface levels) of CD33 (e.g., as measured in vitro using primary human dendritic cells). In some embodiments, an anti-CD33 antibody of the present disclosure reduces the EC of a reference anti-CD33 antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4). 50 at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% lower than 50 In some embodiments, an anti-CD33 antibody of the present disclosure reduces the cellular levels of CD33 (e.g., reduces or lowers cell surface levels) by 100% or more than the EC of a reference anti-CD33 antibody (e.g., an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4). 50 at least about 1 fold, at least about 1.1 fold, at least about 1.5 fold, at least about 2 fold, at least about 3 fold, at least about 4 fold, at least about 5 fold, at least about 6 fold, at least about 7 fold, at least about 8 fold, at least about 9 fold, at least about 10 fold, at least about 12.5 fold, at least about 15 fold, at least about 17.5 fold, at least about 20 fold, at least about 22.5 fold, at least about 25 fold, at least about 27.5 fold, at least about 30 fold, at least about 50 fold, or at least about 100 fold lower EC 50and reduce cellular levels of CD33 (e.g., reduce or lower cell surface levels). In some embodiments, an anti-CD33 antibody of the present disclosure has an EC that is at least 1.2-fold to 1.6-fold or 1.1-fold to 1.6-fold lower than an anti-CD33 antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4. 50 In some embodiments, EC 50 is measured in vitro using primary human dendritic cells. In some embodiments, EC 50 is measured in vitro using primary human monocytes. In some embodiments, EC 50 is measured in vitro using primary human macrophages. In some embodiments, EC 50 is measured in vitro using cultured cells transfected with human CD33. In some embodiments, EC 50 is measured by flow cytometry. 50 is measured at a temperature of approximately 25° C. In some embodiments, EC 50 is measured at a temperature of approximately 35° C. In some embodiments, EC 50 is measured at a temperature of approximately 37° C. In some embodiments, EC 50 is determined using an antibody comprising a constant region that exhibits increased Fc receptor binding. In some embodiments, EC 50 is determined using an antibody comprising a constant region that exhibits reduced Fc receptor binding. In some embodiments, EC 50 is measured using an experimental approach as described in Example 3 below.
[0131] Any in vitro cell-based assay or suitable in vivo model described herein or known in the art can be used to measure inhibition of the interaction (e.g., binding) between CD33 and one or more CD33 ligands. In some embodiments, the anti-CD33 antibodies of the present disclosure inhibit the interaction (e.g., binding) between CD33 and one or more CD33 ligands in any in vitro cell-based assay or suitable in vivo model described herein or known in the art. At least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49%, at least 50%, at least 51%, at least 52%, at least 53%, at least 54%, at least 55%, at least 56%, at least 57%, at least 58%, at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 100%, at least 101%, at least 102%, at least 103%, at least 104%, at least In some embodiments, the inhibitor inhibits at least 59%, at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more.
[0132] In some embodiments, the anti-CD33 antibodies of the present disclosure inhibit cell surface clustering of CD33. In some embodiments, the anti-CD33 antibodies of the present disclosure inhibit the phosphorylation of Tyr-340 and Tyr-358 by Src family tyrosine kinases, such as, but not limited to, LCK and FYN; recruitment and binding of tyrosine-specific protein phosphatases SHP1 and SHP2; recruitment and binding of PLC-γ1, which acts as a guanine nucleotide exchange factor for Dynamini-1; recruitment and binding of SH2-domain-containing proteins (e.g., Crkl); recruitment and binding of the spleen tyrosine kinase Syk; and SH3-SH2- recruitment and binding of SH3 growth factor receptor-bound protein 2 (Grb2); recruitment and binding of multiple SH2-containing proteins; phosphorylation of Ser-307 and Ser-342 by protein kinase C; modulation of expression of soluble receptors for one or more of the anti-inflammatory cytokines IL-4, IL-10, IL-13, IL-35, IL-16, TGF-β, IL-1Ra, G-CSF, and TNF, IFN-β1a, IFN-β1b, or IL-6 in monocytes, macrophages, T cells, dendritic cells, neutrophils, and / or microglia; Decreased calcium mobilization; modulation of expression of one or more pro-inflammatory cytokines IFN-α, IFN-β, IL-1β, TNF-α, IL-6, IL-8, CRP, IL-20 family members, LIF, IFN-γ, OSM, CNTF, GM-CSF, IL-11, IL-12, IL-17, IL-18, IL-23, CXCL10, IL-33, CRP, IL-33, MCP-1, and MIP-1β in monocytes, macrophages, T cells, dendritic cells, neutrophils, and / or microglia; C1qa, C1qB, C1qC, modulation of expression of one or more proteins selected from C1s, C1R, C4, C2, C3, ITGB2, HMOX1, LAT2, CASP1, CSTA, VSIG4, MS4A4A, C3AR1, GPX1, TyroBP, ALOX5AP, ITGAM, SLC7A7, CD4, ITGAX, PYCARD, CD14, CD16, HLA-DR, and CCR2; inhibition of extracellular signal-regulated kinase (ERK) phosphorylation; reduction of tyrosine phosphorylation of multiple cellular proteins; modulation of CC chemokine receptor 7 (CCR7) expression;inhibition of microglial cell chemotaxis toward CCL19-expressing cells and CCL21-expressing cells; activation of phosphoinositide 3-kinase; reduction of monocyte, macrophage, T cell, dendritic cell, and / or microglial cell proliferation; reduction of T cell proliferation induced by dendritic cells, bone marrow-derived dendritic cells, monocytes, microglia, M1 microglia, activated M1 microglia, M2 microglia, macrophages, M1 macrophages, activated M1 macrophages, and / or M2 macrophages; inhibition of osteoclastogenesis, reduction of the rate of osteoclast formation, and or both; reduced viability of neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, helper T cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia, and / or M2 microglia; or reduced viability of neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, helper T cells, cytotoxic T cells, granulocytes, Decreased proliferation of microglia, M1 microglia, activated M1 microglia, and / or M2 microglia; Inhibition of migration of neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, helper T cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia, and / or M2 microglia; Neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages Decreased function of one or more of neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, helper T cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia, and / or M2 microglia; Inhibition of maturation of neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, helper T cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia, and / or M2 microglia;Increased cell death and apoptosis of monocytes, macrophages, T cells, dendritic cells, neutrophils, and / or microglia; decreased phagocytic activity of monocytes, macrophages, T cells, dendritic cells, neutrophils, and / or microglia; decreased proliferation of monocytes, macrophages, T cells, dendritic cells, neutrophils, and / or microglia; decreased overall functionality of monocytes, macrophages, T cells, dendritic cells, neutrophils, and / or microglia; phosphorylation of ITAM-containing receptors; phosphorylation of signaling molecules that mediate ITAM signaling; decreased activation of pattern recognition receptors; decreased activation of Toll-like receptors; decreased damage-related activation of clearance of cellular and protein debris; CD33 and its ligands an interaction between one or more of: an interaction between CD33 and a co-receptor such as CD64; a decrease in one or more types of clearance selected from apoptotic neuron clearance, neural tissue debris clearance, dysfunctional synapse clearance, non-neural tissue debris clearance, bacterial or other foreign body clearance, pathogenic protein clearance, and tumor cell clearance; an inhibition of phagocytosis of one or more of apoptotic neurons, neural tissue debris, non-neural tissue debris, bacteria, other foreign body, pathogenic protein, pathogenic peptide, pathogenic nucleic acid, pathogenic lipid, or tumor cell; an inhibition of clearance of pathogenic nucleic acid (e.g., the pathogenic nucleic acid is an antisense GGCCCC(G2C4) repeat expansion RNA);Amyloid beta, amyloid beta plaques, amyloid precursor protein or its fragments, tau, IAPP, α-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), c9RAN protein, prion protein, PrPSc, huntingtin, calcitonin, superoxide dismutase, ataxin, ataxin 1, ataxin 2, ataxin 3, ataxin 7, ataxin 8, ataxin 10, Lewy bodies, atrial natriuretic factor, islet amyloid polypeptide Tide, insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, transthyretin, lysozyme, β2-microglobulin, gelsolin, keratoepithelin, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) translation products, dipeptide repeat (DPR) peptides, glycine-alanine (GA) repeat peptides, glycine-proline (GP) repeat peptides, glycine-arginine (GR) repeat peptides, proline-alanine (PA) repeat peptides activation of clearance of pathogenic proteins selected from cytotoxic peptides, ubiquitin, and proline-arginine (PR) repeat peptides; inhibition of beneficial immune responses against different types of cancer selected from bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, acute myeloid leukemia, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma, and thyroid cancer; and dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, Creutzfeldt-Jakob disease, and normal Inhibition of beneficial immune responses against different types of neurological disorders selected from pressure hydrocephalus, amyotrophic lateral sclerosis, Huntington's disease, taupathies, Nasu-Hakola disease, stroke, acute trauma, chronic trauma, essential tremor, Behçet's disease, Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, Shy-Drager syndrome, progressive supranuclear palsy, corticobasal ganglionic degeneration, acute disseminated encephalomyelitis, granulomatous disease, sarcoidosis, geriatric diseases, convulsions, spinal cord injury, traumatic brain injury, age-related macular degeneration, glaucoma, retinitis pigmentosa, retinal degeneration, and multiple sclerosis;Inhibition of beneficial immune responses to different types of inflammatory and infectious disorders selected from lupus, acute and chronic colitis, wound healing, Crohn's disease, inflammatory bowel disease, ulcerative colitis, obesity, malaria, respiratory tract infections, sepsis, eye infections, systemic infections, lupus, arthritis, low bone mineral density, osteoporosis, bone formation, osteopetrosis, and Paget's disease of bone; binding to CD33 ligand on tumor cells; binding to CD33 ligand on dendritic cells, bone marrow-derived dendritic cells, monocytes, microglia, T cells, neutrophils, and / or macrophages; binding to CD33 ligand on microglia, macrophages, dendritic cells, monocytes, microglia, macrophages, dendritic cells, and / or macrophages. inhibition of tumor cell killing by one or more of microglia, macrophages, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, helper T cells, or cytotoxic T cells; inhibition of anti-tumor cell proliferation activity by one or more of microglia, macrophages, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, helper T cells, or cytotoxic T cells; inhibition of anti-tumor cell metastasis activity by one or more of microglia, macrophages, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, helper T cells, or cytotoxic T cells; inhibition of tumor cell killing by one or more of immunosuppressive dendritic cells, immunosuppressive macrophages, bone marrow-derived dendritic cells, neutrophils, T cells, helper T cells, or cytotoxic T cells promotion of tumor suppressor cells, tumor-associated macrophages, or regulatory T cells; inhibition of one or more ITAM motif-containing receptors, such as TREM1, TREM2, FcgR, DAP10, and DAP12; inhibition of one or more receptors containing the motif D / Ex0-2YxxL / IX6-8YxxL / I (SEQ ID NO: 104); inhibition of signaling by one or more pattern recognition receptors (PRRs), such as receptors that specify pathogen-associated molecular patterns (PAMPs) and receptors that specify damage-associated molecular patterns (DAMPs); inhibition of signaling by one or more Toll-like receptors inhibition of nuclear signaling; inhibition of the JAK-STAT signaling pathway; inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB); inhibition of PLCγ / PKC / calcium mobilization; inhibition of PI3K / Akt, Ras / MAPK signaling; reduction of expression of one or more inflammatory receptors, such as CD86, expressed on one or more of microglia, macrophages, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, helper T cells, or cytotoxic T cells; increased expression of one or more CD33-dependent genes; normalization of disrupted CD33-dependent gene expression;and inhibiting one or more activities of the CD33 protein, including counteracting one or more of the reduced expression of one or more ITAM-dependent genes, such as NFAT transcription factors;
[0133] In some embodiments, the anti-CD33 antibodies of the present disclosure are directed to, but not limited to, tumor-infiltrating CD3 + Increased number of T cells; CD14 + Myeloid cells, e.g., tumor-infiltrating CD14 + CD14 present in bone marrow cells and blood + Decreased cellular levels of CD33;CD14 in bone marrow cells + Myeloid cells, e.g., tumor-infiltrating CD14 + CD14 present in bone marrow cells and blood +a reduction in the number of myeloid cells; a reduction in PD-L1, PD-L2, B7-H7, B7-H3, CD200R, CD163, and / or CD206 levels in one or more cells, such as myeloid-derived suppressor cells (MDSCs); a decrease in tumor growth rate of solid tumors; a reduction in tumor volume; an increase in the effectiveness of one or more PD-1 inhibitors; an increase in the effectiveness of one or more checkpoint inhibitory and / or immunomodulatory therapies, such as checkpoint inhibitory and / or immunomodulatory therapies targeting one or more of CTL4, the adenosine pathway, PD-L1, PD-L2, OX40, TIM3, LAG3, or any combination thereof; an increase in the effectiveness of one or more chemotherapeutic agents (optionally, one or more of the chemotherapeutic agents is selected from the group consisting of gemcitabine, capecitabine, an anthracycline, doxorubicin (Adriamycin®), epirubicin (Ellence®), and the like). and any combination thereof; enhancing T cell proliferation in the presence of myeloid-derived suppressor cells (MDSCs); inhibiting the differentiation, survival, and / or one or more functions of myeloid-derived suppressor cells (MDSCs); and killing of CD33-expressing immunosuppressive non-tumorigenic myeloid cells and / or non-tumorigenic CD14-expressing cells in solid tumors and associated vasculature when conjugated to a chemical or radiotoxin.
[0134] In some embodiments, the anti-CD33 antibody inhibits the interaction (e.g., binding) between a CD33 protein of the present disclosure and one or more CD33 ligands, including, but not limited to, a CD33 ligand expressed on erythrocytes, a CD33 ligand expressed on bacterial cells, a CD33 ligand expressed on apoptotic cells, a CD33 ligand expressed on tumor cells, a CD33 ligand expressed on viruses, a CD33 ligand expressed on dendritic cells, a CD33 ligand expressed on neurons, a CD33 ligand expressed on glial cells, a CD33 ligand expressed on microglia, a CD33 ligand expressed on astrocytes, a CD33 ligand on beta-amyloid plaques, a CD33 ligand on tau tangles, a CD33 ligand on a pathogenic protein, a CD33 ligand on a pathogenic peptide, a CD33 ligand expressed on macrophages, CD33 ligands include CD33 ligand expressed on natural killer cells, CD33 ligand expressed on T cells, CD33 ligand expressed on helper T cells, CD33 ligand expressed on cytotoxic T cells, CD33 ligand expressed on B cells, CD33 ligand expressed on tumor-embedded immunosuppressive dendritic cells, CD33 ligand expressed on tumor-embedded immunosuppressive macrophages, CD33 ligand expressed on myeloid-derived suppressor cells, CD33 ligand expressed on regulatory T cells, secreted mucin, sialic acid, sialic acid-containing glycolipids, sialic acid-containing glycoproteins, α-2,6-linked sialic acid-containing glycolipids, α-2,6-linked sialic acid-containing glycoproteins, α-2,3-linked sialic acid-containing glycolipids, α-2,3-linked sialic acid-containing glycoproteins, α-1-acid glycoprotein (AGP), CD24 protein, and gangliosides.
[0135] In some embodiments, anti-CD33 antibodies of the present disclosure bind to a CD33 protein of the present disclosure expressed on the cell surface, and the naked antibody inhibits the interaction (e.g., binding) between the CD33 protein and one or more CD33 ligands. In some embodiments, anti-CD33 antibodies of the present disclosure that bind to the CD33 protein inhibit the interaction (e.g., binding) between the CD33 protein and one or more CD33 ligands by reducing the effective level of CD33 that can interact with the protein, either on the cell surface or inside the cell. In some embodiments, anti-CD33 antibodies of the present disclosure that bind to the CD33 protein inhibit the interaction (e.g., binding) between the CD33 protein and one or more CD33 ligands by inducing degradation of CD33.
[0136] As used herein, the level of CD33 can refer to the expression level of the gene encoding CD33, the expression level of one or more transcripts encoding CD33, the expression level of CD33 protein, and / or the amount of CD33 protein present inside and / or on the cell surface. Any method known in the art for measuring the level of gene expression, transcription, translation, and / or protein abundance or localization can be used to determine the level of CD33.
[0137] Additionally, the anti-CD33 antibodies of the present disclosure may be used to treat dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, amyotrophic lateral sclerosis, Huntington's disease, tauopathy, Nasu-Hakola disease, stroke, acute trauma, chronic trauma, lupus, acute and chronic colitis, rheumatoid arthritis, wound healing, Crohn's disease, inflammatory bowel disease, ulcerative colitis, Obesity, malaria, essential tremor, central nervous system lupus, Behçet's disease, Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, Shy-Drager syndrome, progressive supranuclear palsy, corticobasal ganglionic degeneration, acute disseminated encephalomyelitis, granulomatous disease, sarcoidosis, geriatric diseases, convulsions, spinal cord injury, traumatic brain injury, age-related macular degeneration, glaucoma, retinitis pigmentosa, retinal degeneration, respiratory tract infections , sepsis, eye infections, systemic infections, lupus, arthritis, multiple sclerosis, low bone density, osteoporosis, bone formation, osteopetrosis, Paget's disease of bone, bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), multiple myeloma, polycythemia vera, essential thrombocytosis, primary or idiopathic myelofibrosis, primary or idiopathic myelosclerosis, bone marrow-derived tumors, tumors expressing CD33, cancers including thyroid cancer, infections, CNS herpes, parasitic infections, trypanosome infections, Cruzi infections, Pseudomonas aeruginosa infection, Leishmania donovani infection, group B Streptococcus infection, Campylobacter jejuni infection, Neisseria meningiditis infection, HIV type 1, and / or Haemophilus influenza infection.In some embodiments, anti-CD33 antibodies of the present disclosure may be used to induce or promote the survival, maturation, function, migration, or proliferation of one or more immune cells in an individual in need thereof; or to reduce the activity, function, or viability of regulatory T cells, tumor-embedded immunosuppressive dendritic cells, tumor-embedded immunosuppressive macrophages, myeloid-derived suppressor cells, tumor-associated macrophages, acute myeloid leukemia (AML) cells, chronic lymphocytic leukemia (CLL) cells, and / or chronic myeloid leukemia (CML) cells in an individual in need thereof. In some embodiments, anti-CD33 antibodies of the present disclosure are monoclonal antibodies.
[0138] In some embodiments, an isolated anti-CD33 antibody of the present disclosure reduces cellular levels of CD33 (e.g., cell surface levels, intracellular levels, and / or total levels). In some embodiments, an isolated anti-CD33 antibody of the present disclosure induces downregulation of CD33. In some embodiments, an isolated anti-CD33 antibody of the present disclosure induces cleavage of CD33. In some embodiments, an isolated anti-CD33 antibody of the present disclosure induces internalization of CD33. In some embodiments, an isolated anti-CD33 antibody of the present disclosure induces shedding of CD33. In some embodiments, an isolated anti-CD33 antibody of the present disclosure induces degradation of CD33. In some embodiments, an isolated anti-CD33 antibody of the present disclosure induces desensitization of CD33. In some embodiments, an isolated anti-CD33 antibody of the present disclosure acts as a ligand mimic to temporarily activate CD33. In some embodiments, an isolated anti-CD33 antibody of the present disclosure acts as a ligand mimic, transiently activating CD33 before inducing a reduction in cellular levels of CD33 and / or inhibition of the interaction (e.g., binding) between CD33 and one or more CD33 ligands. In some embodiments, an isolated anti-CD33 antibody of the present disclosure acts as a ligand mimic, transiently activating CD33 before inducing CD33 degradation. In some embodiments, an isolated anti-CD33 antibody of the present disclosure acts as a ligand mimic, transiently activating CD33 before inducing CD33 cleavage. In some embodiments, an isolated anti-CD33 antibody of the present disclosure acts as a ligand mimic, transiently activating CD33 before inducing CD33 internalization. In some embodiments, an isolated anti-CD33 antibody of the present disclosure acts as a ligand mimic, transiently activating CD33 before inducing CD33 shedding. In some embodiments, the isolated anti-CD33 antibodies of the present disclosure act as ligand mimetics, transiently activating CD33 before inducing downregulation of CD33 expression.In some embodiments, the isolated anti-CD33 antibodies of the present disclosure act as ligand mimetics, transiently activating CD33 before inducing desensitization of CD33.
[0139] In some embodiments, the isolated anti-CD33 antibodies of the present disclosure are human, humanized, bispecific, monoclonal, multivalent, or chimeric antibodies. Exemplary descriptions of such antibodies are found throughout this disclosure.
[0140] In some embodiments, an anti-CD33 antibody of the present disclosure binds to human CD33 or a homolog thereof (including, but not limited to, a mammalian CD33 protein). In some embodiments, an anti-CD33 antibody of the present disclosure specifically binds to human CD33. In some embodiments, an anti-CD33 antibody of the present disclosure binds to human CD33 and does not cross-react with CD33 orthologs or homologs from other species. In some embodiments, an anti-CD33 antibody of the present disclosure binds to human CD33 but does not bind to cynomolgus CD33. In some embodiments, an anti-CD33 antibody of the present disclosure binds to both human CD33 and cynomolgus CD33.
[0141] In some embodiments, an anti-CD33 antibody of the present disclosure binds to a CD33 protein of the present disclosure expressed on the cell surface and modulates (e.g., induces or inhibits) one or more CD33 activities of the present disclosure after binding to the surface-expressed CD33 protein. In some embodiments, an anti-CD33 antibody of the present disclosure is an inactive antibody.
[0142] Anti-CD33 antibody binding region In some embodiments, the anti-CD33 antibodies of the present disclosure can bind to a conformational epitope. In some embodiments, the anti-CD33 antibodies of the present disclosure can bind to a discontinuous CD33 epitope. In some embodiments, the discontinuous CD33 epitope comprises two or more peptides, three or more peptides, four or more peptides, five or more peptides, six or more peptides, seven or more peptides, eight or more peptides, nine or more peptides, or ten or more peptides. In some embodiments, the anti-CD33 antibodies of the present disclosure can bind to a CD33 epitope comprising one or more peptides. As disclosed herein, a CD33 epitope can comprise one or more peptides comprising 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, or 20 or more amino acid residues of the amino acid sequence of SEQ ID NO:1, or 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, or 20 or more amino acid residues on a mammalian CD33 protein corresponding to the amino acid sequence of SEQ ID NO:1.
[0143] In some embodiments, an anti-CD33 antibody of the present disclosure binds to an epitope of human CD33 that is the same as or overlaps with the CD33 epitope bound by an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4. In some embodiments, an anti-CD33 antibody of the present disclosure binds to essentially the same CD33 epitope bound by an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4.
[0144] In some embodiments, an anti-CD33 antibody of the present disclosure competitively inhibits the binding of an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4. In some embodiments, an anti-CD33 antibody of the present disclosure competes for binding to CD33 (e.g., human CD33) with an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4.
[0145] In some embodiments, an anti-CD33 antibody of the present disclosure competitively inhibits the binding of at least one antibody selected from any of the antibodies listed in Tables 7, 8, 9, 10, 11, and 12. In some embodiments, the anti-CD33 antibodies of the disclosure are 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, 6C7H54, 6C7H55, 6C7H56, 6C7H57, 6C7H58, 6C7H59, 6C7H60, 6C7H61, 6C7H62, 6C7H63, C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof. In some embodiments, the anti-CD33 antibodies of the disclosure are 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, The anti-CD33 antibody that competes for binding to CD33 with one or more antibodies selected from 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof, is selected from the group consisting of 6C7H1, 6C7H2,6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6 C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof, is reduced by an amount ranging from about 50% to 100% compared to binding to CD33 in the absence of the anti-CD33 antibody. In some embodiments, the anti-CD33 antibodies of the disclosure are 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17 , 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H 27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7 H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof, the anti-CD33 antibody competes for binding to CD33 with one or more antibodies selected from 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14,6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C 7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H4 7, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof, is reduced by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% compared to binding to CD33 in the absence of the anti-CD33 antibody. In some embodiments, 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7 H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H3 The anti-CD33 antibodies of the present disclosure that reduce by 100% the binding to CD33 of one or more antibodies selected from 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13,6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C 7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H3 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof, to CD33. In some embodiments, an anti-CD33 antibody and 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, 6C7H54, 6C7H55, 6C7H56, 6C7H57, 6C7H58, 6C7H59, 6C7H60, 6C7H61, 6C7H62, 6C7H63, 6C7 C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H3 3, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7 One or more antibodies selected from the group consisting of anti-CD33 antibodies and 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H 9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C 7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32,6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and and one or more antibodies selected from any combination thereof, at a ratio of 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 0.75:1, 0.5:1, 0.25:1, 0.1:1, 0.075:1, 0.050:1, 0.025:1, 0.01:1, Ratio, 0.0075:Ratio, 0.0050:1 Ratio, 0.0025:1 Ratio, 0.001:Ratio, 0.00075:1 Ratio, 0.00050:1 Ratio, 0.00025:1 Ratio, 0.0001:Ratio, 1:10 Ratio, 1:9 Ratio, 1:8 Ratio, 1:7 Ratio, 1:6 Ratio, 1:5 Ratio, 1:4 Ratio, 1:3 Ratio, 1:2 Ratio, 1:0.75 Ratio, 1:0.5 Ratio , 1:0.25 ratio, 1:0.1 ratio, 1:0.075 ratio, 1:0.050 ratio, 1:0.025 ratio, 1:0.01 ratio, 1:0.0075 ratio, 1:0.0050 ratio, 1:0.0025 ratio, 1:0.001 ratio, 1:0.00075 ratio, 1:0.00050 ratio, 1:0.00025 ratio, or 1:0.0001 ratio. In some embodiments, the anti-CD33 antibody is selected from the group consisting of 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, and 6C7H52, 6C7H53, and 6C7H54, and any combination thereof. In some embodiments, the anti-CD33 antibody is 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7 H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6 C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37 , 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof, and in an amount of about a 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 35-fold, 40-fold, 45-fold, 50-fold, 55-fold, 60-fold, 65-fold, 70-fold, 75-fold, 80-fold, 85-fold, 90-fold, 95-fold, or 100-fold excess relative to the amount of one or more antibodies selected from
[0146] In some embodiments, the anti-CD33 antibodies of the present disclosure bind to an epitope on human CD33 that is the same as or overlaps with a CD33 epitope bound by at least one antibody selected from any of the antibodies listed in Tables 7, 8, 9, 10, 11, and 12. In some embodiments, the anti-CD33 antibodies of the disclosure are 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, 6C7H54, 6C7H55, 6C7H56, 6C7H57, 6C7H58, 6C7H59, 6C7H60, 6C7H61, 6C7H62, 6C7H63, It binds to an epitope on human CD33 that is the same as or overlaps with a CD33 epitope bound by at least one antibody selected from 7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54.
[0147] In some embodiments, the anti-CD33 antibodies of the present disclosure bind to essentially the same CD33 epitope as that bound by at least one antibody selected from any of the antibodies listed in Tables 7, 8, 9, 10, 11, and 12. In some embodiments, the anti-CD33 antibodies of the disclosure are selected from the group consisting of 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, and 6C7H52, 6C7H53, and 6C7H54. Details of exemplary methods for mapping antibody-binding epitopes are presented in Morris (1996) "Epitope Mapping Protocols," in Methods in Molecular Biology, vol. 66 (Humana Press, Totowa, NJ).
[0148] In some embodiments, the anti-CD33 antibodies of the disclosure are 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, 6C7H54, 6C7H55, 6C7H56, 6C7H57, 6C7H58, 6C7H59, 6C7H60, 6C7H61, 6C7H62, 6C7H63, C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof, for binding to CD33 (e.g., human CD33).
[0149] Any suitable competition or CD33 binding assay known in the art, such as BIAcore analysis, ELISA assay, or flow cytometry, can be used to detect whether the anti-CD33 antibodies are 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26,
[0063] It can be determined whether the antibody competes for binding to CD33 with one or more antibodies selected from 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof. In an exemplary competitive assay, immobilized CD33 or cells expressing CD33 on their cell surface are incubated in a solution containing a labeled first antibody that binds to CD33 (e.g., human or non-human primate) and an unlabeled second antibody whose ability to compete with the first antibody for binding to CD33 is tested. The second antibody may be present in hybridoma supernatant. As a control, immobilized CD33 or CD33-expressing cells are incubated in a solution containing the labeled first antibody but not the unlabeled second antibody. After incubation under conditions that allow the first antibody to bind to CD33, excess unbound antibody is removed and the amount of label associated with the immobilized CD33 or CD33-expressing cells is measured. A substantial reduction in the amount of label associated with the immobilized CD33 or CD33-expressing cells in the test sample compared to the control sample indicates that the second antibody competes with the first antibody for binding to CD33.See Harlow and Lane (1988) Antibodies: A Laboratory Manual ch. 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).
[0150] Light and heavy chain variable regions of anti-CD33 antibodies In some embodiments, an anti-CD33 antibody of the disclosure comprises a heavy chain variable region comprising one or more (e.g., one or more, two or more, or all three) HVRs selected from HVR-H1, HVR-H2, and HVR-H3 (shown in Table 7). In some embodiments, the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3 (shown in Table 7). In some embodiments, an anti-CD33 antibody of the disclosure comprises a light chain variable region comprising one or more (e.g., one or more, two or more, or all three) HVRs selected from HVR-L1, HVR-L2, and HVR-L3 (shown in Table 8). In some embodiments, the heavy chain variable region comprises HVR-L1, HVR-L2, and HVR-L3 (shown in Table 8).
[0151] In some embodiments, the anti-CD33 antibodies of the disclosure are (a) 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, 6C7H54, 6C7H55, 6C7H56, 6C7H57, 6C7H58, 6C7H59, 6C7H60, 6C7H61, 6C7H62, 6C7H6 a light chain variable region comprising at least one, two, or three HVRs selected from HVR-L1, HVR-L2, and HVR-L3 of any one of an antibody selected from C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, 6C7H54, and any combination thereof;and / or (b) 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34 , 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, 6C7H54, and any combination thereof. In some embodiments, the anti-CD33 antibodies of the disclosure are selected from the group consisting of: (i) 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7 HVR-L1 comprising an antibody amino acid sequence selected from H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54;(ii) 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C an HVR-L2 comprising an antibody amino acid sequence selected from 7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54; (iii) 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15 , 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6 an HVR-L3 comprising an antibody amino acid sequence selected from C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54;(iv)6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15 , 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6 HVR-H1 comprising an amino acid sequence of an antibody selected from C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54. ;(v)6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C HVR-H2 comprising an antibody amino acid sequence selected from 7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54;and (vi) 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32 , 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and In some embodiments, HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3 are 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, 6C7H54, 6C7H55, 6C7H56, 6C7H57, 6C7H58, 6C7H59, 6C7H60 comprising the sequence of an EU or Kabat CDR, Chothia CDR, or contact CDR of an antibody selected from C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54, and any combination thereof;
[0152] In some embodiments, an anti-CD33 antibody of the present disclosure comprises a light chain variable domain and a heavy chain variable domain, wherein the light chain variable domain comprises one or more of (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (b) HVR-L2 comprising an amino acid sequence selected from SEQ ID NOs: 52 to 55, and (c) HVR-L3 comprising an amino acid sequence selected from SEQ ID NOs: 58 to 62, and / or the heavy chain variable domain comprises one or more of (a) HVR-H1 comprising an amino acid sequence selected from SEQ ID NOs: 8 to 30, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, and (c) HVR-H3 comprising an amino acid sequence selected from SEQ ID NOs: 38 to 40.
[0153] In some embodiments, an anti-CD33 antibody of the disclosure comprises a heavy chain variable domain and a light chain variable domain, wherein (a) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 8, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 38, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 52, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; and (b) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 8 and HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33. (c) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 9, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 54, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58. (d) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 9, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (e) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 9, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, and HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47 (f) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 10, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58, (g) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 11, and HVR-H2 comprises(h) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 12, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58. HVR-H1 comprises the amino acid sequence of SEQ ID NO: 13, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58, (j) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 14, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39 (k) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 15, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (l) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 16 amino acid sequence, wherein HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (m) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 17, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, and HVR-L2 comprises(n) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 18, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (o) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 19, and HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39; VR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58, (p)HVR-H1 comprises the amino acid sequence of SEQ ID NO: 20, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58 (q) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 21, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (r) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 22, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, and HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47 HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (s) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 23, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (t) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 24, and HVR-H2 comprises(u) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 25, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58; (v) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 26, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58, (w) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 27, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39 (x) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 28, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, (y) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 58, (y ... HVR-H1 comprises the amino acid sequence of SEQ ID NO: 29, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 59; (z) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 29, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, and HVR-L2 comprises(aa) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 29, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, HVR-L3 comprises the amino acid sequence of SEQ ID NO: 61, and (bb) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 29. , HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 62, (cc) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 30, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 40, and HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47 wherein HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 59, (dd) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 30, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 40, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 60, and (ee) HVR-H1 comprises the amino acid sequence of SEQ ID NO: HVR-H1 comprises the amino acid sequence of SEQ ID NO: 30, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 40, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 61; (ff) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 30, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 40, and HVR-L1 (gg) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 30, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 60, and (hh) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 30. (ii) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 23, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 62; (jj) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 23, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 62, (kk) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 30, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 (ll) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 30, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 59, (ll) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 30, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 61;(mm) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 28, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 59; (nn) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 28, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 39, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 61.
[0154] In some embodiments, the anti-CD33 antibodies of the disclosure are 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, Any one of antibodies selected from 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54. one light chain variable region; and / or 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H28, 6C7H2 9, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54.In some embodiments, the anti-CD33 antibody of the disclosure is selected from the group consisting of those listed in Table 11, or 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, Any one of antibodies selected from 6C7H27, 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54. one light chain variable region; and / or one of the amino acids listed in Table 12, or 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27, 6C7H2 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54.
[0155] In some embodiments, an anti-CD33 antibody of the present disclosure comprises a light chain variable region comprising an amino acid sequence selected from any of SEQ ID NOs: 94-103, and / or a heavy chain variable domain comprising an amino acid sequence selected from any of SEQ ID NOs: 65-93. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 94, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 65. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 94, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 66. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 95, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 65. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 95, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 67. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 95, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 66. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 96, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 65. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:96, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:67. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:68. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:98, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:69. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:69. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:94, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:65. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:99, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:69. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:70.In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:71. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:72. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:73. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:74. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:75. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:76. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:77. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:78. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:79. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:80. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:81. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:82. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:83. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:84.In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:85. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:86. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:87. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:97, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:88. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:100, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:89. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:101, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:89. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO:102, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO:89. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 89. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 90. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 90. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 90. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 90. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 91. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 91.In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 91. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 91. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 92. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 92. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 93. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 93. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 101, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 83. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 103, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 83. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 92. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 92. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 93. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 93. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 100, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 83. In some embodiments, the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 102, and the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 83.
[0156] In some embodiments, the anti-CD33 antibody is a V H and V as in any of the above embodiments. L In some embodiments, an anti-CD33 antibody is provided, comprising: H and V as in any of the above embodiments. L In one embodiment, an anti-CD33 antibody of the disclosure comprises a V selected from SEQ ID NOs: 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, and 93. H and V selected from SEQ ID NOs: 94, 95, 96, 97, 98, 99, 100, 101, 102, and 103. L In some embodiments, the anti-CD33 antibody comprises the sequences 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27 , 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54. H Sequence and V L Contains arrays.
[0157] In some embodiments, the anti-CD33 antibody is a V Hand V as in any of the above embodiments. L In some embodiments, an anti-CD33 antibody of the disclosure is provided comprising a V selected from SEQ ID NOs: 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, and 93. H and V selected from SEQ ID NOs: 94, 95, 96, 97, 98, 99, 100, 101, 102, and 103. L In some embodiments, the anti-CD33 antibody comprises the sequences 6C7H1, 6C7H2, 6C7H3, 6C7H4, 6C7H5, 6C7H6, 6C7H7, 6C7H8, 6C7H9, 6C7H10, 6C7H11, 6C7H12, 6C7H13, 6C7H14, 6C7H15, 6C7H16, 6C7H17, 6C7H18, 6C7H19, 6C7H20, 6C7H21, 6C7H22, 6C7H23, 6C7H24, 6C7H25, 6C7H26, 6C7H27 , 6C7H28, 6C7H29, 6C7H30, 6C7H31, 6C7H32, 6C7H33, 6C7H34, 6C7H35, 6C7H36, 6C7H37, 6C7H38, 6C7H39, 6C7H40, 6C7H41, 6C7H42, 6C7H43, 6C7H44, 6C7H45, 6C7H46, 6C7H47, 6C7H48, 6C7H49, 6C7H50, 6C7H51, 6C7H52, 6C7H53, and 6C7H54. H Sequence and V L Contains arrays.
[0158] In another aspect, an anti-CD33 antibody of the disclosure comprises a heavy chain variable domain (V) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, or 93. HIn certain embodiments, a V has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, or 93. H The sequence may contain substitutions (e.g., conservative substitutions), insertions, or deletions relative to a reference sequence, but an anti-CD33 antibody comprising the sequence retains the ability to bind to CD33. In certain embodiments, a total of 1 to 10 amino acids are substituted, inserted, and / or deleted in SEQ ID NO: 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, or 93. In certain embodiments, a total of 1 to 5 amino acids are substituted, inserted, and / or deleted in SEQ ID NO: 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, or 93. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, the anti-CD33 antibody comprises a VVR of SEQ ID NO: 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, or 93. H In one particular embodiment, V H comprises one, two, or three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of HVR-H1 set forth in Table 7; (b) HVR-H2 comprising the amino acid sequence of HVR-H1 set forth in Table 7; and (c) HVR-H3 comprising the amino acid sequence of HVR-H3 set forth in Table 7.
[0159] In another aspect, an anti-CD33 antibody of the disclosure comprises a light chain variable domain (V) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 94, 95, 96, 97, 98, 99, 100, 101, 102, or 103. L In certain embodiments, a V has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence of SEQ ID NO: 94, 95, 96, 97, 98, 99, 100, 101, 102, or 103. L The sequence may contain substitutions (e.g., conservative substitutions), insertions, or deletions relative to a reference sequence, but an anti-CD33 antibody comprising the sequence retains the ability to bind to CD33. In some embodiments, a total of 1 to 10 amino acids are substituted, inserted, and / or deleted in SEQ ID NO: 94, 95, 96, 97, 98, 99, 100, 101, 102, or 103. In certain embodiments, a total of 1 to 5 amino acids are substituted, inserted, and / or deleted in SEQ ID NO: 94, 95, 96, 97, 98, 99, 100, 101, 102, or 103. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the HVRs (i.e., in the FRs). Optionally, an anti-CD33 antibody may contain a VVR of SEQ ID NO: 94, 95, 96, 97, 98, 99, 100, 101, 102, or 103. L In one particular embodiment, V L comprises one, two, or three HVRs selected from: (a) an HVR-L1 comprising the amino acid sequence of HVR-L1 set forth in Table 8; (b) an HVR-L2 comprising the amino acid sequence of HVR-L2 set forth in Table 8; and (c) an HVR-L3 comprising the amino acid sequence of HVR-L3 set forth in Table 8.
[0160] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 8; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 38; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 52; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H1. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H2. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H3. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H4. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H5. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H6. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H7.
[0161] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 8, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H8.
[0162] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 54, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H9.
[0163] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H10.
[0164] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 55, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H11.
[0165] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 10, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H12.
[0166] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 11, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H13.
[0167] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 12, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H14.
[0168] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 13, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H15.
[0169] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 14, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H16.
[0170] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 15, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H17.
[0171] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 16, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H18.
[0172] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 17, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H19.
[0173] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 18, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H20.
[0174] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 19, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H21.
[0175] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H22.
[0176] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 21, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H23.
[0177] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 22, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H24.
[0178] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H25.
[0179] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 24, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H26.
[0180] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 25, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H27.
[0181] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 26, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H28.
[0182] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 27, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H29.
[0183] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 28, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 58. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H30.
[0184] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 29; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H31. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H39. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H49.
[0185] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 29; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H32. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H40. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H43.
[0186] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 29; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H33. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H41. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H50.
[0187] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 29; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 62. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H34. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H42. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H44.
[0188] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 40, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H35.
[0189] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 40, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H36.
[0190] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 40, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H37.
[0191] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 40, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 62. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H38.
[0192] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H45.
[0193] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 62. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H46.
[0194] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H47.
[0195] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 62. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H48.
[0196] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H51.
[0197] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 30, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H52.
[0198] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 59. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H53.
[0199] In some embodiments, provided herein is an anti-CD33 antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 61. In some embodiments, the anti-CD33 antibody is anti-CD33 monoclonal antibody 6C7H54.
[0200] Provided herein are anti-CD33 antibodies that are useful, for example, for the diagnosis or treatment of CD33-mediated and / or CD33-associated diseases, conditions, or disorders.
[0201] In some embodiments, the anti-CD33 antibody according to any of the above embodiments is a monoclonal antibody, including a humanized and / or human antibody. In some embodiments, the anti-CD33 antibody is an antibody fragment, e.g., an Fv, Fab, Fab', scFv, diabody, or F(ab')2 fragment. In some embodiments, the anti-CD33 antibody is a substantially full-length antibody, e.g., an IgG1 antibody, an IgG2a antibody, or other antibody class or isotype as defined herein.
[0202] In some embodiments, an anti-CD33 antibody according to any of the above embodiments may incorporate any of the features described below, either alone or in combination.
[0203] Anti-CD33 antibody binding affinity In some embodiments of any of the antibodies provided herein, the antibody has a cytotoxicity of <1 μM, <100 nM, <10 nM, <1 nM, <0.1 nM, <0.01 nM, or <0.001 nM (e.g., 10 -8 M or less, e.g., 10 -8 M~10 -13 M, e.g., 10 -9 M~10 -13The antibody has a dissociation constant (Kd) of M (M). The dissociation constant can be determined by any analytical technique, including any biochemical or biophysical technique, such as ELISA, surface plasmon resonance (SPR), biolayer interferometry (see, e.g., the Octet System by ForteBio), isothermal titration calorimetry (ITC), differential scanning calorimetry (DSC), circular dichroism (CD), stopped-flow analysis, and colorimetric or fluorescent protein melting analysis. In one embodiment, the Kd is measured by a radiolabeled antigen binding assay (RIA). In some embodiments, the RIA is performed using a Fab version of the antibody of interest and its antigen, e.g., as described in Chen et al. J. Mol. Biol. 293:865-881 (1999). In some embodiments, Kd is measured using a BIACORE surface plasmon resonance assay, e.g., an assay using a BIACORE-2000 or BIACORE-3000 (BIAcore, Inc., Piscataway, NJ) performed at 25°C using an immobilized antigen CM5 chip at about 10 response units (RU). D is determined using a monovalent antibody (e.g., Fab) or a full-length antibody. In some embodiments, K D is determined using the monovalent form of the full-length antibody.
[0204] antibody fragment In some embodiments of any of the antibodies provided herein, the antibody is an antibody fragment. Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')2, Fv, and scFv fragments, as well as other fragments described below. For a review of specific antibody fragments, see Hudson et al. Nat. Med. 9:129-134 (2003). For a review of scFv fragments, see, e.g., WO 93 / 16185 and U.S. Pat. Nos. 5,571,894 and 5,587,458. For a detailed discussion of Fab and F(ab')2 fragments that contain salvage receptor-binding epitope residues and have extended in vivo half-lives, see U.S. Pat. No. 5,869,046.
[0205] Diabodies are antibody fragments with two antigen-binding sites that can be bivalent or bispecific. See, for example, EP404097, WO1993 / 01161, Hudson et al. Nat. Med. 9:129-134 (2003). Triabodies and tetrabodies are also described in Hudson et al. Nat. Med. 9:129-134 (2003). Single-domain antibodies are antibody fragments that contain all or part of the heavy chain variable domain or all or part of the light chain variable domain of an antibody. In certain embodiments, single-domain antibodies are human single-domain antibodies (see, for example, U.S. Patent No. 6,248,516).
[0206] Antibody fragments can be produced by a variety of techniques, including, but not limited to, proteolytic digestion of intact antibodies as well as production by recombinant host cells (e.g., E. coli or phage), as described herein.
[0207] Chimeric and humanized antibodies In some embodiments of any of the antibodies provided herein, the antibody is a chimeric antibody. Particular chimeric antibodies are described, for example, in U.S. Patent No. 4,816,567. In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate such as a monkey) and a human constant region. In a further example, a chimeric antibody is a "class-switched" antibody whose class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.
[0208] In some embodiments of any of the antibodies provided herein, the antibody is a humanized antibody. Typically, non-human antibodies are humanized to reduce immunogenicity in humans while retaining the specificity and affinity of the parent non-human antibody. In certain embodiments, humanized antibodies are substantially non-immunogenic in humans. In certain embodiments, humanized antibodies have substantially the same target affinity as an antibody from another species from which the humanized antibody is derived. See, e.g., U.S. Patent Nos. 5,530,101, 5,693,761, 5,693,762, and 5,585,089. In certain embodiments, amino acids in antibody variable domains have been identified that can be modified to reduce immunogenicity without diminishing the native affinity of the antigen-binding domain. See, e.g., U.S. Patent Nos. 5,766,886 and 5,869,619. Generally, a humanized antibody comprises one or more variable domains in which the HVRs (or portions thereof) are derived from a non-human antibody and the FRs (or portions thereof) are derived from human antibody sequences. A humanized antibody optionally also comprises at least a portion of a human constant region. In some embodiments, some FR residues in a humanized antibody are substituted with corresponding residues from the non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity.
[0209] Humanized antibodies and methods for making them are reviewed, for example, in Almagro et al. Front. Biosci. 13:161 9-1633 (2008) and further described, for example, in U.S. Patent Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409. Human framework regions that can be used for humanization include framework regions selected using the "best-fit" method (see, e.g., Sims et al. J. Immunol. 151:2296 (1993)); framework regions derived from consensus sequences of human antibodies with specific subgroups of light or heavy chain variable regions (see, e.g., Carter et al. Proc. Natl. Acad. Sci. USA 89:4285 (1992) and Presta et al. J. Immunol. 151:2623 (1993)); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson Front. Biosci. 13:1619-1633 (2008)); and framework regions obtained from screening of FR libraries (see, e.g., Baca et al. al. J. Biol. Chem. 272:10678-10684 (1997) and Rosok et al. J. Biol. Chem. 271:22611-22618 (1996)).
[0210] Human antibodies In some embodiments of any of the antibodies provided herein, the antibody is a human antibody. Human antibodies can be produced using various techniques known in the art. Human antibodies are generally described in van Dijk et al. Curr. Opin. Pharmacol. 5:368-74 (2001) and Lonberg Curr. Opin. Immunol. 20:450-459 (2008).
[0211] Human antibodies can be prepared by administering immunogens to transgenic animals that have been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigen challenge. Mouse strains deficient in mouse antibody production and carrying large fragments of human Ig loci may be engineered with the expectation that such strains will produce human antibodies without producing mouse antibodies. Large human Ig fragments preserve the highly variable genetic diversity and proper regulation of antibody production and expression. By utilizing mouse mechanisms for antibody diversification and selection and the lack of immune tolerance to human proteins, the human antibody repertoires replicated in these mouse strains can yield high-affinity, fully human antibodies against any antigen of interest, including human antigens. Hybridoma technology can be used to generate and select antigen-specific human MAbs with desired specificities. Certain exemplary methods are described in U.S. Patent No. 5,545,807, EP 546073, and EP 546073. See also, e.g., U.S. Patent Nos. 6,075,181 and 6,150,584, describing XENOMOUSE™ technology, U.S. Patent No. 5,770,429, describing HUMAB® technology, U.S. Patent No. 7,041,870, describing KM MOUSE® technology, and U.S. Patent Application Publication No. US2007 / 0061900, describing VELOCIMOUSE® technology. The human variable regions from intact antibodies produced by such animals can be further modified, for example, by combining with different human constant regions.
[0212] Human antibodies can also be produced by hybridoma-based methods. Human myeloma cell lines and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described (see, e.g., Kozbor J. Immunol. 133:3001 (1984) and Boerner et al. J. Immunol. 147:86 (1991)). Human antibodies produced via human B cell hybridoma technology are also described in Li et al. Proc. Natl. Acad. Sci. USA, 1 03:3557-3562 (2006). Additional methods include those described, for example, in U.S. Patent No. 7,189,826, which describes the production of monoclonal human IgM antibodies from hybridoma cell lines. Human hybridoma technology (trioma technology) is also described in Vollmers et al., Histology and Histopathology 20(3):927-937 (2005) and Vollmers et al., Methods and Findings in Experimental and Clinical Pharmacology 27(3):185-91 (2005). Human antibodies can also be produced by isolating Fv clone variable domain sequences selected from a human-derived phage display library. Such variable domain sequences may then be combined with desired human constant domains. Techniques for selecting human antibodies from antibody libraries are described below.
[0213] In some embodiments of any of the antibodies provided herein, the antibody is a human antibody isolated by in vitro methods and / or screening of combinatorial libraries for antibodies with the desired activity or activities. Suitable examples include, but are not limited to, phage display (CAT, Morphosys, Dyax, Biosite / Medarex, Xoma, Symphogen, Alexion (formerly Proliferon), Affimed), ribosome display (CAT), yeast display (Adimab), and the like. In certain phage display methods, repertoires of VH and VL genes are separately cloned by polymerase chain reaction (PCR) and randomly recombined into phage libraries, which can then be screened for antigen-binding phage, as described in Winter et al. Ann. Rev. Immunol. 12:433-455 (1994). For example, various methods for generating phage display libraries and screening such libraries for antibodies with the desired binding characteristics are known in the art. See also Sidhu et al. J. Mol. Biol. 338(2):299-310, 2004; Lee et al. J. Mol. Biol. 340(5):1073-1093, 2004; Fellouse Proc. Natl. Acad. Sci. USA 101(34):12467-12472 (2004); and Lee et al. J. Immunol. Methods 284(-2):119-132 (2004). Phages typically display antibody fragments as either single-chain Fv (scFv) fragments or Fab fragments. Libraries derived from immunized sources yield high-affinity antibodies against the immunogen without the need to construct hybridomas. Alternatively, as described in Griffiths et al. EMBO J. 12:725-734 (1993), naive repertoires can be cloned (e.g., from humans) to provide a single source of antibodies against a wide range of non-self and self antigens without any immunization.Finally, naive libraries can also be synthetically generated by cloning unrearranged V gene segments from stem cells and using PCR primers containing random sequences to encode the highly variable HVR3 region and achieve rearrangement in vitro, as described in Hoogenboom et al. J. Mol. Biol., 227:381-388, 1992. Patent publications describing human antibody phage libraries include, for example, U.S. Patent No. 5,750,373, and U.S. Patent Publication Nos. 2007 / 0292936 and 2009 / 0002360. Antibodies isolated from human antibody libraries are considered human antibodies or human antibody fragments herein.
[0214] Constant region including the Fc region In certain embodiments, the anti-CD33 antibody is an antagonist antibody. In certain embodiments, the anti-CD33 antibody is an agonist antibody or an inactive antibody. In some embodiments, the anti-CD33 antibody of the present disclosure is of the IgG class, IgM class, or IgA class. In some embodiments, the anti-CD33 antibody of the present disclosure is of the IgG class and has an IgG1, IgG2, IgG3, or IgG4 isotype. In some embodiments of any of the antibodies provided herein, the antibody comprises an Fc. In some embodiments, the Fc is a human IgG1, IgG2, IgG3, and / or IgG4 isotype. In some embodiments, the antibody is of the IgG class, IgM class, or IgA class.
[0215] In certain embodiments, the Fc region comprises an Fc variant listed below in Table E. The Fc variant may or may not include a C-terminal lysine residue as indicated in Table E. TIFF0007586813000005.tif247170TIFF0007586813000006.tif254170TIFF0007586813000007.tif255170TIFF0007586813000008.tif220170
[0216] Additional anti-CD33 antibodies, e.g., antibodies that specifically bind to the CD33 proteins of the present disclosure, can be identified, screened, and / or analyzed for their physical / chemical properties and / or biological activity by various assays known in the art.
[0217] Anti-CD33 antibodies capable of binding to Fcγ receptors In some embodiments, anti-CD33 antibodies of the present disclosure retain the ability to bind to Fcγ receptors. In some embodiments, such antibodies, when possessing the correct epitope specificity compatible with receptor activation, may be characterized by, for example, clustering and transiently stimulating CD33 receptors. In some embodiments, such antibodies may subsequently act as long-lasting inhibitors of CD33 expression and / or one or more activities of the CD33 protein by inducing CD33 degradation, CD33 desensitization, CD33 cleavage, CD33 internalization, CD33 shedding, downregulation of CD33 expression, and / or lysosomal degradation of CD33.
[0218] In vivo, the anti-CD33 antibodies of the present disclosure can cluster receptors and transiently activate CD33 by any one or more of several possible mechanisms. Some human antibody isotypes, such as IgG2, have the inherent ability to cluster receptors or hold receptors in a clustered structure due to their unique structure, thereby transiently activating receptors such as CD33 without binding to Fc receptors (e.g., White et al., (2015) Cancer Cell 27, 138-148).
[0219] In some embodiments, other antibodies can cluster receptors (e.g., CD33) by binding to Fcg receptors on neighboring cells. In some embodiments, antibody aggregation can occur when the constant IgG Fc region of an antibody binds to an Fcg receptor, and these antibodies can then bind to and aggregate receptors via their variable regions (Chu et al. (2008) Mol Immunol, 45:3926-3933, and Wilson et al., (2011) Cancer Cell 19, 101-113). In some embodiments, binding to the inhibitory Fcg receptor FcgR (FcgRIIB), which does not induce cytokine secretion, oxidative burst, increased phagocytosis, and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), is a preferred method for clustering antibodies in vivo because binding to FcgRIIB is not associated with adverse immune response effects.
[0220] There are other mechanisms by which the anti-CD33 antibodies of the present disclosure may cluster receptors. For example, antibody fragments (e.g., Fab fragments) cross-linked together can be used to cluster receptors (e.g., CD33) in a manner similar to antibodies with Fc regions that bind to Fcg receptors, as described above. In some embodiments, cross-linked antibody fragments (e.g., Fab fragments) induce receptor clustering on the cell surface and can transiently function as agonist antibodies when bound to the appropriate epitope on the target (e.g., CD33).
[0221] Thus, in some embodiments, antibodies of the present disclosure that bind to CD33 protein may include antibodies that, by virtue of their epitope specificity, bind to CD33 and transiently activate one or more CD33 activities, and then, for example, reduce the cellular level of CD33, inhibit one or more CD33 activities, and / or inhibit the interaction (e.g., binding) between CD33 and one or more CD33 ligands. In some embodiments, such antibodies can bind to a ligand-binding site on CD33 to transiently mimic the action of a natural ligand, or can stimulate a target antigen to transduce a signal by binding to one or more domains that are not the ligand-binding site. In some embodiments, such antibodies do not interfere with ligand binding. In some embodiments, regardless of whether the antibody binds to the ligand binding site on CD33, the antibody may subsequently act as a long-lasting inhibitor of CD33 expression and / or one or more activities of the CD33 protein by inducing CD33 degradation, CD33 desensitization, CD33 cleavage, CD33 internalization, CD33 shedding, downregulation of CD33 expression, and / or lysosomal degradation of CD33.
[0222] In some embodiments, the anti-CD33 antibodies of the present disclosure are antibodies that transiently induce one or more activities of the CD33 protein. In some embodiments, the antibodies transiently induce one or more activities after binding to CD33 protein expressed intracellularly. In some embodiments, the CD33 protein is expressed on the cell surface. In some embodiments, one or more activities of the CD33 protein that are transiently induced by an anti-CD33 antibody of the present disclosure include, but are not limited to, phosphorylation of Tyr-340 and Tyr-358 by Src family tyrosine kinases, such as LCK and FYN; recruitment and binding of tyrosine-specific protein phosphatases SHP1 and SHP2; recruitment and binding of PLC-γ1, which acts as a guanine nucleotide exchange factor for Dynamini-1; recruitment and binding of SH2-domain-containing proteins (e.g., Crkl); recruitment and binding of the spleen tyrosine kinase Syk; recruitment and binding of SH3-SH2-SH3 growth factor receptor-bound protein 2 (Grb2); recruitment and binding of multiple SH2-containing proteins; phosphorylation of Ser-307 and Ser-342 by protein kinase C; and expression of monocytes, macrophages, and the like. modulation of the expression of one or more anti-inflammatory cytokines IL-4, IL-10, IL-13, IL-35, IL-16, TGF-β, IL-1Ra, G-CSF, and soluble receptors for TNF, IFN-β1a, IFN-β1b, or IL-6 in monocytes, macrophages, T cells, dendritic cells, neutrophils, and / or microglia; reduction of intracellular calcium mobilization; modulation of the expression of one or more pro-inflammatory cytokines IFN-a4, IFN-b, IL-1β, TNF-α, IL-6, IL-8, CRP, IL-20 family members, LIF, IFN-γ, OSM, CNTF, GM-CSF, IL-11, IL-12, IL-17, IL-18, IL-23, CXCL10, IL-33, CRP, IL-33, MCP-1, and MIP-1-β in microglia;Modulation of expression of one or more proteins selected from C1qa, C1qB, C1qC, C1s, C1R, C4, C2, C3, ITGB2, HMOX1, LAT2, CASP1, CSTA, VSIG4, MS4A4A, C3AR1, GPX1, TyroBP, ALOX5AP, ITGAM, SLC7A7, CD4, ITGAX, PYCARD, CD14, CD16, HLA-DR, and CCR2; inhibition of extracellular signal-regulated kinase (ERK) phosphorylation; reduction of tyrosine phosphorylation of multiple cellular proteins; C modulation of C chemokine receptor 7 (CCR7) expression; inhibition of microglial cell chemotaxis toward CCL19-expressing cells and CCL21-expressing cells; activation of phosphoinositide 3-kinase; reduction of monocyte, macrophage, T cell, dendritic cell, and / or microglia proliferation; T cell proliferation induced by dendritic cells, bone marrow-derived dendritic cells, monocytes, microglia, M1 microglia, activated M1 microglia, M2 microglia, macrophages, M1 macrophages, activated M1 macrophages, and / or M2 macrophages reduced osteoclast proliferation; inhibition of osteoclastogenesis, a decrease in the rate of osteoclast formation, or both; reduced viability of neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, helper T cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia, and / or M2 microglia; reduction of proliferation of neutrophils, monocytes, osteoclasts, T cells, helper T cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia, and / or M2 microglia; inhibition of migration of neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, helper T cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia, and / or M2 microglia;Decreased function of one or more of neutrophils, dendritic cells, bone marrow-derived dendritic cells, macrophages, M1 macrophages, activated M1 macrophages, M2 macrophages, monocytes, osteoclasts, T cells, helper T cells, cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia, and / or M2 microglia; ... Inhibition of maturation of cytotoxic T cells, granulocytes, microglia, M1 microglia, activated M1 microglia, and / or M2 microglia; Increased cell death and apoptosis of monocytes, macrophages, T cells, dendritic cells, neutrophils, and / or microglia; Reduced phagocytic activity of monocytes, macrophages, T cells, dendritic cells, neutrophils, and / or microglia; Reduced proliferation of monocytes, macrophages, T cells, dendritic cells, neutrophils, and / or microglia; and / or a decrease in overall microglial functionality, phosphorylation of ITAM-containing receptors; phosphorylation of signaling molecules that mediate ITAM signaling; a decrease in activation of pattern recognition receptors; a decrease in activation of Toll-like receptors; a decrease in damage-related activation of clearance of cellular and protein debris; an interaction between CD33 and one or more of its ligands; an interaction between CD33 and a co-receptor such as CD64; a decrease in one or more types of clearance selected from apoptotic neuron clearance, dysfunctional synapse clearance, neural tissue debris clearance, non-neural tissue debris clearance, bacterial or other foreign body clearance, pathogenic protein clearance, and tumor cell clearance; an inhibition of phagocytosis of one or more of apoptotic neurons, neural tissue debris, non-neural tissue debris, bacteria, other foreign body, pathogenic protein, pathogenic peptide, pathogenic nucleic acid, pathogenic lipid, or tumor cell; an inhibition of clearance of pathogenic nucleic acid (e.g., the pathogenic nucleic acid is an antisense GGCCCC(G2C4) repeat expansion RNA);Amyloid beta, amyloid beta plaques, amyloid precursor protein or its fragments, tau, IAPP, α-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), c9RAN protein, prion protein, PrPSc, huntingtin, calcitonin, superoxide dismutase, ataxin, ataxin 1, ataxin 2, ataxin 3, ataxin 7, ataxin 8, ataxin 10, Lewy bodies, atrial natriuretic factor, islet amyloid polypeptide Tide, insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, transthyretin, lysozyme, β2-microglobulin, gelsolin, keratoepithelin, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) translation products, dipeptide repeat (DPR) peptides, glycine-alanine (GA) repeat peptides, glycine-proline (GP) repeat peptides, glycine-arginine (GR) repeat peptides, proline-alanine (PA) repeat peptides activation of clearance of pathogenic proteins selected from cytotoxic peptides, ubiquitin, and proline-arginine (PR) repeat peptides; inhibition of beneficial immune responses against different types of cancer selected from bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, acute myeloid leukemia, pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma, and thyroid cancer; and dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, Creutzfeldt-Jakob disease, and normal Inhibition of beneficial immune responses against different types of neurological disorders selected from pressure hydrocephalus, amyotrophic lateral sclerosis, Huntington's disease, taupathies, Nasu-Hakola disease, stroke, acute trauma, chronic trauma, essential tremor, Behçet's disease, Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, Shy-Drager syndrome, progressive supranuclear palsy, corticobasal ganglionic degeneration, acute disseminated encephalomyelitis, granulomatous disease, sarcoidosis, geriatric diseases, convulsions, spinal cord injury, traumatic brain injury, age-related macular degeneration, glaucoma, retinitis pigmentosa, retinal degeneration, and multiple sclerosis;Inhibition of beneficial immune responses to different types of inflammatory and infectious disorders selected from lupus, acute and chronic colitis, wound healing, Crohn's disease, inflammatory bowel disease, ulcerative colitis, obesity, malaria, respiratory tract infections, sepsis, eye infections, systemic infections, lupus, arthritis, low bone density, osteoporosis, bone formation, osteopetrosis, and Paget's disease of bone; apoptotic neurons, neural tissue debris, dysfunctional synapses, non-neural tissue debris, bacteria, other foreign bodies, pathogenic proteins, pathogenic peptides, pathogenic nucleic acids, or tumors Inhibition of phagocytosis of one or more tumor cells (the pathogenic nucleic acid can be an antisense GGCCCC (G2C4) repeat expansion RNA, and the pathogenic protein can be amyloid beta, amyloid beta oligomers, amyloid beta plaques, amyloid precursor protein or a fragment thereof, tau, IAPP, α-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), c9RAN protein, prion protein, PrPSc, huntingtin, calcitonin). , superoxide dismutase, ataxin, ataxin 1, ataxin 2, ataxin 3, ataxin 7, ataxin 8, ataxin 10, Lewy bodies, atrial natriuretic factor, islet amyloid polypeptide, insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, transthyretin, lysozyme, β2-microglobulin, gelsolin, keratoepithelin, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) translation products, dipeptide repeat (DPR) peptides, glycine-alanine (GA) repeat peptides, glycine-proline (GP) repeat peptides, glycine-arginine (GR) repeat peptides, proline-alanine (PA) repeat peptides, ubiquitin, and proline-arginine (PR) repeat peptides, and the tumor cells may be bladder cancer, brain cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, renal cell carcinoma, renal pelvis cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, the tumor may be derived from a cancer selected from pancreatic cancer, prostate cancer, ovarian cancer, fibrosarcoma, or thyroid cancer); binding to CD33 ligand on tumor cells; binding to CD33 ligand on dendritic cells, bone marrow-derived dendritic cells, monocytes, microglia, T cells, neutrophils, and / or macrophages; inhibition of tumor cell killing by one or more of microglia, macrophages, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, helper T cells, or cytotoxic T cells; microglia, macrophages, dendritic cells, bone marrow-derived dendritic cells, Inhibition of anti-tumor cell proliferation activity of one or more of neutrophils, T cells, helper T cells, or cytotoxic T cells; inhibition of anti-tumor cell metastasis activity of one or more of microglia, macrophages, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, helper T cells, or cytotoxic T cells; promotion of immunosuppressive dendritic cells, immunosuppressive macrophages, myeloid-derived suppressor cells, tumor-associated macrophages, or regulatory T cells; one or more ITAMs such as TREM1, TREM2, FcgR, DAP10, and DAP12 Inhibition of motif-containing receptors; inhibition of one or more receptors containing the motif D / Ex0-2YxxL / IX6-8YxxL / I (SEQ ID NO: 104); inhibition of signaling by one or more pattern recognition receptors (PRRs), such as receptors that specify pathogen-associated molecular patterns (PAMPs) and receptors that specify damage-associated molecular patterns (DAMPs); inhibition of signaling by one or more Toll-like receptors; inhibition of the JAK-STAT signaling pathway; inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) inhibition of PLCγ / PKC / calcium mobilization; inhibition of PI3K / Akt, Ras / MAPK signaling; modulation of the expression of one or more inflammatory receptors, such as CD86, expressed on one or more of microglia, macrophages, dendritic cells, bone marrow-derived dendritic cells, neutrophils, T cells, helper T cells, or cytotoxic T cells; increased expression of one or more CD33-dependent genes; normalization of disrupted CD33-dependent gene expression; and decreased expression of one or more ITAM-dependent genes, such as NFAT transcription factors.Anti-CD33 antibodies of the present disclosure can be tested for their ability to transiently induce one or more activities of CD33 protein using any suitable technique or assay known in the art and disclosed herein. Regardless of the activity that such antibodies transiently induce, such antibodies may subsequently act as long-term inhibitors of CD33 expression and / or one or more activities of CD33 protein by inducing CD33 degradation, CD33 desensitization, CD33 cleavage, CD33 internalization, CD33 shedding, downregulation of CD33 expression, and / or lysosomal degradation of CD33. In some embodiments, CD33 antibodies transiently induce one or more activities of CD33 protein independent of binding to an Fc receptor.
[0223] Exemplary antibody Fc isotypes and modifications are set forth below in Table B. In some embodiments, an anti-CD33 antibody of the disclosure capable of binding to an Fcγ receptor has an Fc isotype listed in Table B below. TIFF0007586813000009.tif255170TIFF0007586813000010.tif122170
[0224] In addition to the isotypes listed in Table B, without wishing to be bound by theory, it is believed that antibodies of the human IgG1 or IgG3 isotype and variants thereof (e.g., Strohl (2009) Current Opinion in Biotechnology 2009, 20:685-691) that bind to human Fcg receptors I, IIA, IIC, IIIA, IIIB and / or mouse Fcg receptors I, III and IV may also act as transient agonist antibodies.
[0225] In some embodiments, the Fcγ receptor-binding antibody is of the IgG class, IgM class, or IgA class. In some embodiments, the Fcγ receptor-binding antibody has an IgG1, IgG2, IgG3, or IgG4 isotype. In some embodiments, the antibody comprises one or more (e.g., one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, or all thirteen) amino acid substitutions in the Fc region selected from the group consisting of C127S, L234A, L234F, L235A, L235E, S267E, K322A, L328F, A330S, P331S, E345R, E430G, and S440Y, in any combination (residue positions according to EU numbering). In some embodiments, the Fc region comprises an amino acid substitution at position E430G. In some embodiments, the Fc region comprises amino acid substitutions at positions L234A, L235A, and P331A. In some embodiments, the Fc region comprises amino acid substitutions at positions L234A, L235A, and P331A. In some embodiments, the Fc region comprises amino acid substitutions at positions K322A and E430G. In some embodiments, the Fc region comprises amino acid substitutions at positions P331S and E430G. In some embodiments, the Fc region comprises amino acid substitutions at positions A330S, P331S, and E430G. In some embodiments, the Fc region comprises amino acid substitutions at positions K322A, A330S, and P331S. In some embodiments, the Fc region comprises amino acid substitutions at positions K322A, P331S, and E430G. In some embodiments, the Fc region comprises amino acid substitutions at positions A330S, P331S, and E430G. In some embodiments, the Fc region comprises amino acid substitutions at positions S267E and L328F. In some embodiments, the Fc region comprises an amino acid substitution at position C127S. In some embodiments, the Fc region comprises amino acid substitutions at positions E345R, E430G, and S440Y. In some embodiments, the Fc region comprises an amino acid substitution at position P331S.In some embodiments, the Fc region comprises amino acid substitutions at positions L234A, L235A, and P331S. In some embodiments, the Fc region comprises amino acid substitutions at positions S267E and L328F. In some embodiments, the numbering of the above amino acid substitutions is according to EU numbering.
[0226] In certain embodiments, the Fcγ receptor-binding antibody has an IgG2 isotype. In some embodiments, the Fcγ receptor-binding antibody comprises a human IgG2 constant region. In some embodiments, the human IgG2 constant region comprises an Fc region. In some embodiments, the Fcγ receptor-binding antibody binds to an inhibitory Fc receptor. In certain embodiments, the inhibitory Fc receptor is inhibitory Fc-γ receptor IIB (FcγIIB). In some embodiments, the Fc region comprises one or more modifications. For example, in some embodiments, the Fc region comprises one or more amino acid substitutions (e.g., compared to a wild-type Fc region of the same isotype). In some embodiments, the one or more amino acid substitutions are V234A (Alegre et al., (1994) Transplantation 57:1537-1543.31; Xu et al., (2000) Cell Immunol, 200:16-26), G237A (Cole et al. (1999) Transplantation, 68:563-571), H268Q, V309L, A330S, P331S (US2007 / 0148167; Armour et al. (1999) Eur J Immunol 29:2613-2624; Armour et al. (2000) The Haematology Journal 1(Suppl. 1):27; Armour et al. (2000) The Haematology Journal 1 (Suppl. 1):27), C232S, and / or C233S (White et al. (2015) Cancer Cell 27, 138-148), S267E, L328F (Chu et al., (2008) Mol Immunol, 45:3926-3933), M252Y, S254T, and / or T256E, where the amino acid positions are according to the EU numbering rules.
[0227] In some embodiments, the Fcγ receptor-binding antibody has an IgG2 isotype comprising a heavy chain constant domain comprising a C127S amino acid substitution, where the amino acid position is according to the EU numbering convention (White et al., (2015) Cancer Cell 27, 138-148; Lightle et al., (2010) PROTEIN SCIENCE 19:753-762; and WO2008079246).
[0228] In some embodiments, the Fcγ receptor-binding antibody has an IgG2 isotype comprising a kappa light chain constant domain comprising a C214S amino acid substitution, where the amino acid position is according to the EU numbering convention (White et al., (2015) Cancer Cell 27, 138-148; Lightle et al., (2010) PROTEIN SCIENCE 19:753-762; and WO2008079246).
[0229] In certain embodiments, the Fcγ receptor-binding antibody has an IgG1 isotype. In some embodiments, the Fcγ receptor-binding antibody comprises a mouse IgG1 constant region. In some embodiments, the Fcγ receptor-binding antibody comprises a human IgG1 constant region. In some embodiments, the human IgG1 constant region comprises an Fc region. In some embodiments, the Fcγ receptor-binding antibody binds to an inhibitory Fc receptor. In certain embodiments, the inhibitory Fc receptor is inhibitory Fc-γ receptor IIB (FcγIIB). In some embodiments, the Fc region comprises one or more modifications. For example, in some embodiments, the Fc region comprises one or more amino acid substitutions (e.g., compared to a wild-type Fc region of the same isotype).In some embodiments, the one or more amino acid substitutions are N297A (Bolt S et al. (1993) Eur J Immunol 23:403-411), D265A (Shields et al. (2001) RJBiol. Chem. 276, 6591-6604), D270A, L234A, L235A (Hutchins et al. (1995) Proc Natl Acad Sci USA, 92:11980-11984; Alegre et al., (1994) Transplantation 57:1537-1543.31; Xu et al., (2000) Cell Immunol, 200:16-26), G237A (Alegre et al. (1994) Transplantation 57:1537-1543.31; Xu et al. (2000) Cell Immunol,200:16-26), P238D, L328E, E233D, G237D, H268D, P271G, A330R, C226S, C229S, E233P, L234V, L234F, L235E (McEarchern et al. al.,(2007)Blood,109:1185-1192), P331S(Sazinsky et al.,(2008)Proc Natl Acad Sci USA 2008,105:20167-20172), S267E, L328F, A330L, M252Y, S254T, T256E, N297Q, P238S, P238A, A327Q, A327G, P329A, K322A, and / or T394D, where the amino acid positions are according to the EU numbering rules.
[0230] In some embodiments, the antibody comprises an IgG2 isotype heavy chain constant domain 1 (CH1) and hinge region (White et al., (2015) Cancer Cell 27, 138-148). In a specific embodiment, the IgG2 isotype CH1 and hinge region comprises the amino acid sequence ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCP (SEQ ID NO: 105). In some embodiments, the antibody Fc region comprises a S267E amino acid substitution, a L328F amino acid substitution, or both, and / or a N297A or N297Q amino acid substitution, wherein amino acid positions are according to EU numbering rules.
[0231] In certain embodiments, the Fcγ receptor-binding antibody has an IgG4 isotype. In some embodiments, the Fcγ receptor-binding antibody comprises a human IgG4 constant region. In some embodiments, the human IgG4 constant region comprises an Fc region. In some embodiments, the Fcγ receptor-binding antibody binds to an inhibitory Fc receptor. In certain embodiments, the inhibitory Fc receptor is inhibitory Fc-γ receptor IIB (FcγIIB). In some embodiments, the Fc region comprises one or more modifications. For example, in some embodiments, the Fc region comprises one or more amino acid substitutions (e.g., compared to a wild-type Fc region of the same isotype). In some embodiments, the one or more amino acid substitutions are selected from L235A, G237A, S228P, L236E (Reddy et al., (2000) J Immunol, 164:1925-1933), S267E, E318A, L328F, M252Y, S254T, and / or T256E, where the amino acid positions are according to the EU numbering convention.
[0232] In certain embodiments, the Fcγ receptor-binding antibody has a hybrid IgG2 / 4 isotype. In some embodiments, the Fcγ receptor-binding antibody comprises an amino acid sequence comprising amino acids 118 to 260 (according to EU numbering) of human IgG2 and amino acids 261 to 447 (according to EU numbering) of human IgG4 (WO1997 / 11971; WO2007 / 106585).
[0233] In certain embodiments, the antibody comprises a murine IgG4 constant region (Bartholomaeus, et al. (2014). J. Immunol. 192, 2091-2098).
[0234] In some embodiments, the Fc region further comprises one or more additional amino acid substitutions selected from the group consisting of A330L, L234F, L235E, or P331S (according to EU), and any combination thereof.
[0235] In certain embodiments, the antibody comprises one or more amino acid substitutions in the Fc region at residue positions selected from C127S, L234A, L234F, L235A, L235E, S267E, K322A, L328F, A330S, P331S, E345R, E430G, S440Y, and any combination thereof, where residue numbering is according to EU numbering. In some embodiments, the Fc region comprises amino acid substitutions at positions E430G, L234A, L235A, and P331S, where residue position numbering is according to EU numbering. In some embodiments, the Fc region comprises amino acid substitutions at positions E430G and P331S, where residue position numbering is according to EU numbering. In some embodiments, the Fc region comprises amino acid substitutions at positions E430G and K322A, where the numbering of the residue positions is according to EU numbering. In some embodiments, the Fc region comprises amino acid substitutions at positions E430G, A330S, and P331S, where the numbering of the residue positions is according to EU numbering. In some embodiments, the Fc region comprises amino acid substitutions at positions E430G, K322A, A330S, and P331S, where the numbering of the residue positions is according to EU numbering. In some embodiments, the Fc region comprises amino acid substitutions at positions E430G, K322A, and A330S, where the numbering of the residue positions is according to EU numbering. In some embodiments, the Fc region comprises amino acid substitutions at positions E430G, K322A, and P331S, where the numbering of the residue positions is according to EU numbering. In some embodiments, the Fc region comprises amino acid substitutions at positions S267E and L328F, where the numbering of the residue positions is according to EU numbering. In some embodiments, the Fc region comprises amino acid substitutions at position C127S, where the numbering of the residue positions is according to EU numbering. In some embodiments, the Fc region comprises amino acid substitutions at positions E345R, E430G, and S440Y, where the numbering of the residue positions is according to EU numbering. In some embodiments, the Fc region comprises amino acid substitutions at positions L234A, L235A, and P331S, where the numbering of the residue positions is according to EU numbering.
[0236] inert antibody Another class of anti-CD33 antibodies of the present disclosure includes inactive antibodies. As used herein, an "inactive" antibody refers to an antibody that specifically binds to its target antigen (e.g., CD33) but does not modulate (e.g., reduce / inhibit or activate / induce) antigen function. For example, in the case of CD33, an inactive antibody does not modulate the cellular levels of CD33, does not modulate the interaction (e.g., binding) between CD33 and one or more CD33 ligands, or does not modulate one or more activities of the CD33 protein. In some embodiments, an antibody that does not have the ability to cluster CD33 on the cell surface can be an inactive antibody, even if it has an epitope specificity compatible with receptor activation.
[0237] In some embodiments, antibodies that bind to CD33 protein may include antibodies that bind to CD33 but, due to their epitope specificity or characteristics, do not reduce cellular levels of CD33 and / or do not inhibit the interaction (e.g., binding) between CD33 and one or more CD33 ligands. In some embodiments, such antibodies can be used, for example, as cargo for delivering toxins (e.g., chemotherapeutic drugs) to tumor cells. Thus, in some embodiments, antibodies of the present disclosure are inactive antibodies that bind to CD33 but are unable to reduce cellular levels of CD33, inhibit the interaction (e.g., binding) between CD33 and one or more CD33 ligands, or induce one or more activities of the CD33 protein.
[0238] Antibodies that do or do not reduce cellular levels of CD33 on cells can be combined with an inactive Fc region that exhibits reduced binding to one or more Fcg receptors. Examples of such Fc regions and modifications are listed in Table C below. In some embodiments, antibodies comprising an inactive Fc region have an Fc isotype listed in Table C below.
[0239] Inhibitory anti-CD33 antibody A third class of anti-CD33 antibodies of the present disclosure includes antibodies that block or otherwise inhibit one or more CD33 activities. In some embodiments, antibodies that bind to CD33 protein can include antibodies that reduce cellular levels of CD33 (e.g., cell surface levels of CD33), inhibit the interaction (e.g., binding) between CD33 and / or one or more CD33 ligands, or inhibit one or more activities of the CD33 protein. Such antibodies inhibit one or more activities of the CD33 protein by either preventing the interaction (e.g., binding) between CD33 and one or more CD33 ligands, or by preventing signal transduction from the extracellular domain of CD33 into the cytoplasm of the cell in the presence of one or more CD33 ligands. The antibodies may also inhibit one or more activities of the CD33 protein by reducing cell surface levels of CD33 by inducing CD33 degradation, CD33 desensitization, CD33 cleavage, CD33 internalization, CD33 shedding, downregulation of CD33 expression, and / or lysosomal degradation of CD33. In some embodiments, such anti-CD33 antibodies may not temporarily activate CD33.
[0240] In some embodiments, the anti-CD33 antibodies of the present disclosure may have the epitope specificity of the transient anti-CD33 agonist antibodies of the present disclosure, but have an Fc domain that is incapable of binding to Fcg receptors and, therefore, is incapable of, for example, transiently clustering and activating CD33.
[0241] In some embodiments, the anti-CD33 antibodies of the present disclosure have one or more of the following activities, including but not limited to: the ability to decrease binding of the CD33 protein to one or more CD33 ligands, such as sialic acid-containing glycolipids or sialic acid-containing glycoproteins; the ability to decrease binding of suppressors of cytokine signaling (SOCS) proteins (e.g., SOCS3 proteins) to the CD33 protein; the ability to increase proteasomal degradation of the CD33 protein; the ability to increase the activity of circulating dendritic cells, macrophages, monocytes, T cells, and / or microglia. Its ability to reduce the functional expression of CD33 on the surface of glial cells, its ability to reduce the phosphorylation of Tyr-340 and Tyr-358 by Src family tyrosine kinases such as LCK and FYN, its ability to reduce the recruitment and binding of tyrosine-specific protein phosphatases SHP1 and SHP2, its ability to reduce the recruitment and binding of PLC-g1, which acts as a guanine nucleotide exchange factor for Dynamin-1, its ability to reduce the recruitment and binding of Crkl, its ability to reduce the recruitment and binding of the spleen tyrosine kinase Syk, its ability to reduce the recruitment and binding of SH3-SH2-SH3 formation the ability to decrease the recruitment and binding of long factor receptor-binding protein 2 (Grb2), the ability to decrease the recruitment and binding of multiple SH2-containing proteins, the ability to increase intracellular calcium mobilization, the ability to modulate the production of the proinflammatory cytokines IL-1β, IL-8, and TNF-α, the ability to decrease the activation of phosphoinositide 3-kinase, the ability to increase the proliferation of monocytes, macrophages, dendritic cells, T cells, and / or microglia, the ability to increase the survival of monocytes, macrophages, dendritic cells, T cells, and / or microglia, the ability to increase the proliferation of multiple cellular proteins the ability to increase tyrosine phosphorylation of phosphoproteins, the ability to increase the phagocytic activity of monocytes, macrophages, dendritic cells, and / or microglia, the ability to increase cell proliferation of monocytes, macrophages, dendritic cells, T cells, and / or microglia, the ability to increase phosphorylation of signaling molecules that mediate ITAM signaling, the ability to increase the function of pattern recognition receptors, the ability to increase the function of Toll-like receptors, the ability to increase the function of damage-associated molecular pattern (DAMP) receptors, the ability to modulate the expression of CC chemokine receptor 7 (CCR7),and the ability to increase the clearance of cellular and protein debris.
[0242] In some embodiments, the anti-CD33 antibodies of the disclosure have an Fc region that exhibits reduced binding to one or more Fcg receptors. Examples of such Fc regions and modifications are set forth in Table C below. In some embodiments, the antibodies have an Fc isotype listed in Table C below.
[0243] Antibody Fc isotypes with reduced binding to Fcγ receptors In some embodiments, the anti-CD33 antibody with reduced binding to Fcγ receptors has an Fc isotype listed in Table C below. TIFF0007586813000011.tif218170
[0244] In certain embodiments, the anti-CD33 antibody has an IgG1 isotype. In some embodiments, the antibody comprises a mouse IgG1 constant region. In some embodiments, the antibody comprises a human IgG1 constant region. In some embodiments, the human IgG1 constant region comprises an Fc region. In some embodiments, the Fc region comprises one or more modifications. For example, in some embodiments, the Fc region comprises one or more amino acid substitutions (e.g., compared to a wild-type Fc region of the same isotype).
[0245] In some embodiments, the one or more amino acid substitutions are selected from the group consisting of N297A, N297Q (Bolt S et al. (1993) Eur J Immunol 23:403-411), D265A, D270A, L234A, L235A (McEarchern et al., (2007) Blood, 109:1185-1192), C226S, C229S (McEarchern et al., (2007) Blood, 109:1185-1192), P238S (Davis et al., (2007) J Rheumatol, 34:2204-2210), E233P, L234V (McEarchern et al. al., (2007) Blood, 109:1185-1192), P238A, A327Q, A327G, P329A (Shields RL, et al., (2001) J Biol Chem. 276(9):6591-604), K322A, L234F, L235E (Hezareh, et al. al.,(2001)J Virol 75,12161-12168;Oganesyan et al.,(2008).Acta Crystallographica 64,700-704), P331S(Oganesyan et al.,(2008)Acta Crystallographica 64,700-704), T394D(Wilkinson et al. al.(2013)MAbs 5(3):406-417), A330L, M252Y, S254T, and / or T256E, where amino acid positions are according to EU numbering. In certain embodiments, the Fc region further comprises an amino acid deletion at a position corresponding to glycine 236 (according to EU numbering).
[0246] In some embodiments, the anti-CD33 antibody has an IgG1 isotype comprising a heavy chain constant region comprising a C220S amino acid substitution (according to EU numbering). In some embodiments, the Fc region further comprises one or more additional amino acid substitutions selected from A330L, L234F, L235E, and / or P331S (according to EU numbering). In certain embodiments, the anti-CD33 antibody has an IgG2 isotype. In some embodiments, the anti-CD33 antibody comprises a human IgG2 constant region. In some embodiments, the human IgG2 constant region comprises an Fc region. In some embodiments, the Fc region comprises one or more modifications. For example, in some embodiments, the Fc region comprises one or more amino acid substitutions (e.g., compared to a wild-type Fc region of the same isotype). In some embodiments, the one or more amino acid substitutions are selected from P238S, V234A, G237A, H268A, H268Q, H268E, V309L, N297A, N297Q, V309L, A330S, P331S, C232S, C233S, M252Y, S254T, and / or T256E, where the amino acid positions are according to the EU numbering convention (Vafa O. et al., (2014) Methods 65:114-126).
[0247] In certain embodiments, the anti-CD33 antibody has an IgG4 isotype. In some embodiments, the anti-CD33 antibody comprises a human IgG4 constant region. In some embodiments, the human IgG4 constant region comprises an Fc region. In some embodiments, the Fc region comprises one or more modifications. For example, in some embodiments, the Fc region comprises one or more amino acid substitutions (e.g., compared to a wild-type Fc region of the same isotype). In some embodiments, the one or more amino acid substitutions are E233P, F234V, L235A, G237A, E318A (Hutchins et al. (1995) Proc Natl Acad Sci USA, 92:11980-11984), S228P, L234A / F234A, L236E, S241P, L248E (Reddy et al., (2000) J Immunol, 164:1925-1933; Angal et al., (1993) Mol Immunol. 30(1):105-8; US8614299 B2; Vafa O. et al., (2014) Methods 65:114-126), T394D, M252Y, S254T, T256E, N297A, and / or N297Q, where amino acid positions are according to EU numbering. In some embodiments, the antibody has an IgG4 isotype and contains an S228P amino acid substitution at residue position 228, an F234A amino acid substitution at residue position 234, and an L235A amino acid substitution at residue position 235 (residue positions are according to EU numbering).
[0248] In some embodiments, the Fc region further comprises one or more additional amino acid substitutions selected from M252Y, S254T, and / or T256E, where the amino acid positions are according to the EU numbering convention.
[0249] Further IgG mutations In some embodiments, one or more of the IgG1 variants described herein can be combined with the A330L mutation (Lazar et al., (2006) Proc Natl Acad Sci USA, 103:4005-4010), or one or more of the L234F, L235E, and / or P331S mutations (Sazinsky et al., (2008) Proc Natl Acad Sci USA, 105:20167-20172), to abolish complement activation, where amino acid positions are according to EU numbering conventions. In some embodiments, the IgG variants described herein can be combined with one or more mutations that improve the human serum half-life of the anti-CD33 antibody (e.g., M252Y, S254T, T256E mutations according to the EU numbering convention) (Dall'Acqua et al., (2006) J Biol Chem, 281:23514-23524, and Strohl et al., (2009) Current Opinion in Biotechnology, 20:685-691).
[0250] In some embodiments, the IgG4 variants of the present disclosure can be combined with the S228P mutation (according to the EU numbering convention) (Angal et al., (1993) Mol Immunol, 30:105-108) and / or one or more of the mutations described in Peters et al., (2012) J Biol Chem. 13;287(29):24525-33) to improve antibody stabilization.
[0251] bispecific antibody Certain aspects of the present disclosure relate to bispecific antibodies that bind to one or more domains on the CD33 protein of the present disclosure and a second antigen. Methods for generating bispecific antibodies are well known in the art and are described herein. In some embodiments, a bispecific antibody of the present disclosure binds to one or more amino acid residues of a CD33 protein of the present disclosure, for example, one or more amino acid residues of human CD33 (SEQ ID NO: 1), or amino acid residues on a CD33 protein that correspond to the amino acid residues of SEQ ID NO: 1. In some embodiments, a bispecific antibody of the present disclosure recognizes a first antigen and a second antigen. In some embodiments, the first antigen is a CD33 protein or a naturally occurring variant thereof. In some embodiments, the second antigen is also a CD33 protein or a naturally occurring variant thereof. In some embodiments, the second antigen is an antigen that promotes transport across the blood-brain barrier (see, e.g., Gabathuler R., Neurobiol. Dis. 37 (2010) 48-57). Such second antigens include, but are not limited to, transferrin receptor (TR), insulin receptor (HIR), insulin-like growth factor receptor (IGFR), low-density lipoprotein receptor-related proteins 1 and 2 (LPR-1 and 2), diphtheria toxin receptor, CRM197, llama single-domain antibody, TMEM30(A), protein transduction domain, TAT, Syn-B, penetratin, polyarginine peptides, angiopep peptides such as ANG1005 (see, e.g., Gabathuler, 2010), and other cell surface proteins abundant on blood-brain barrier endothelial cells (see, e.g., Daneman et al., PLoS One. 2010 Oct 29;5(10):e13741).In some embodiments, the second antigen is selected from the group consisting of, but not limited to, amyloid beta, amyloid beta oligomers, amyloid beta plaques, amyloid precursor protein or fragments thereof, tau, IAPP, alpha-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), c9RAN protein, prion protein, PrPSc, huntingtin, calcitonin, superoxide dismutase, ataxin, ataxin 1, ataxin 2, ataxin 3, ataxin 7, ataxin 8, ataxin 10, Lewy bodies, atrial natriuretic factor, islet amyloid polypeptide, The pathogenic proteins include insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, transthyretin, lysozyme, β2-microglobulin, gelsolin, keratoepithelin, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) translation products, dipeptide repeat (DPR) peptides, glycine-alanine (GA) repeat peptides, glycine-proline (GP) repeat peptides, glycine-arginine (GR) repeat peptides, proline-alanine (PA) repeat peptides, ubiquitin, and proline-arginine (PR) repeat peptides. In some embodiments, the second antigen is one or more ligands and / or proteins expressed on immune cells, including, but not limited to, CD40, OX40, ICOS, CD28, CD137 / 4-1BB, CD27, GITR, PD-L1, CTLA4, PD-L2, PD-1, B7-H3, B7-H4, HVEM, LIGHT, BTLA, CD38, TIGIT, VISTA, KIR, GAL9, TIM1, TIM3, TIM4, A2AR, LAG3, DR5, CD39, CD70, CD73, TREM1, TREM2, Siglec-5, Siglec-7, Siglec-9, Siglec-11, SirpA, CD47, CSF1-receptor, CD3, and phosphatidylserine. In some embodiments, the second antigen is a protein, lipid, polysaccharide, or glycolipid expressed on one or more tumor cells.
[0252] antibody fragment Certain aspects of the present disclosure relate to antibody fragments that bind to one or more of the CD33 proteins, naturally occurring variants of CD33 proteins, and disease variants of CD33 proteins of the present disclosure. In some embodiments, the antibody fragment is a Fab, Fab', Fab'-SH, F(ab')2, Fv, or scFv fragment.
[0253] In some embodiments, the antibody fragment is used in combination with a second CD33 antibody and / or a CD33 antibody that is specifically targeted to amyloid beta, amyloid beta oligomers, amyloid beta plaques, amyloid precursor protein or fragments thereof, tau, IAPP, α-synuclein, TDP-43, FUS protein, C9orf72 (chromosome 9 open reading frame 72), c9RAN protein, prion protein, PrPSc, huntingtin, calcitonin, superoxide dismutase, ataxin, ataxin 1, ataxin B, amyloid precursor protein ... 2, ataxin 3, ataxin 7, ataxin 8, ataxin 10, Lewy bodies, atrial natriuretic factor, islet amyloid polypeptide, insulin, apolipoprotein AI, serum amyloid A, medin, prolactin, transthyretin, lysozyme, β2-microglobulin, gelsolin, keratoepithelin, cystatin, immunoglobulin light chain AL, S-IBM protein, repeat-associated non-ATG (RAN) translation products, dipeptide repeat (DPR) peptides, glycine-alanine (GA) repeats and / or in combination with one or more antibodies that specifically bind to a pathogenic protein selected from the group consisting of CD40, OX40, ICOS, CD28, CD137 / 4-1BB, CD27, GITR, PD-L1, CTLA4, PD-L2, PD-1, B7- The antibody may be used in combination with one or more antibodies that bind to an immunomodulatory protein selected from the group consisting of H3, B7-H4, HVEM, LIGHT, BTLA, CD38, TIGIT, VISTA,...
Claims
1. 1. An isolated antibody that binds to CD33, said antibody comprising a heavy chain variable region comprising HVR-H1, HVR-H2, and HVR-H3, and a light chain variable region comprising HVR-L1, HVR-L2, and HVR-L3; HVR-H1 comprises the amino acid sequence of SEQ ID NO:8, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:9, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:54, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:9, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:9, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:55, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:10, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:11, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:12, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:13, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:14, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:15, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:16, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:17, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:18, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:19, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:20, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:21, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:22, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:23, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:24, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:25, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:26, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:27, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:28, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:58; HVR-H1 comprises the amino acid sequence of SEQ ID NO:29, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:59; HVR-H1 comprises the amino acid sequence of SEQ ID NO:29, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:60; HVR-H1 comprises the amino acid sequence of SEQ ID NO:29, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:61; HVR-H1 comprises the amino acid sequence of SEQ ID NO:29, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:62; HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:40, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:59; HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:40, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:60; HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:40, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:61; HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:40, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:62; HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:60; HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:62; HVR-H1 comprises the amino acid sequence of SEQ ID NO:23, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:60; HVR-H1 comprises the amino acid sequence of SEQ ID NO:23, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:62; HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:59; HVR-H1 comprises the amino acid sequence of SEQ ID NO:30, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:61; HVR-H1 comprises the amino acid sequence of SEQ ID NO:23, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:59; or An antibody, wherein HVR-H1 comprises the amino acid sequence of SEQ ID NO:23, HVR-H2 comprises the amino acid sequence of SEQ ID NO:33, HVR-H3 comprises the amino acid sequence of SEQ ID NO:39, HVR-L1 comprises the amino acid sequence of SEQ ID NO:47, HVR-L2 comprises the amino acid sequence of SEQ ID NO:53, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:
61.
2. The antibody, a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:68, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:97; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:69, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:98; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:69, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:97; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:69, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:99; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:70, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:97; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:71, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:97; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:72, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:97; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:73, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:97; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:74, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:97; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:75, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:97; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:76, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:97; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:77, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:97; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:78, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:97; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:79, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:97; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:80, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:97; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:81, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:97; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:82, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:97; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:83, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:97; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:84, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:97; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:85, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:97; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:86, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:97; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:87, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:97; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:88, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:97; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:89, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:100; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:89, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:101; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:89, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:102; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:89, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:103; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:90, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:100; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:90, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:101; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:90, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:102; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:90, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:103; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:91, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:100; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:91, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:101; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:91, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:102; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:91, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:103; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:92, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:101; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:92, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:103; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:93, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:101; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:93, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:103; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:83, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:101; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:83, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:103; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:92, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:100; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:92, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:102; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:93, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:100; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:93, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:102; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:83, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:100; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:83, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:102; a heavy chain comprising the amino acid sequence of SEQ ID NO: 120 and a light chain comprising the amino acid sequence of SEQ ID NO: 122; or A heavy chain comprising the amino acid sequence of SEQ ID NO: 121, and a light chain comprising the amino acid sequence of SEQ ID NO:
122. The antibody described in claim 1.
3. The antibody of claim 1, wherein the heavy chain variable region comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39, and the light chain variable region comprises HVR-L1 comprising the amino acid sequence of SEQ ID NO: 47, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 53, and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
61.
4. The antibody of claim 2, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:83 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
102.
5. The antibody of claim 1, (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 120, and a light chain comprising the amino acid sequence of SEQ ID NO: 122; or (b) a heavy chain comprising the amino acid sequence of SEQ ID NO: 121, and a light chain comprising the amino acid sequence of SEQ ID NO:
122. The antibody of claim 2 or 4.
6. (i) the antibody is a monoclonal antibody; and / or (ii) An antibody according to any one of claims 1 to 5, wherein the antibody is of the IgG class, the IgM class, or the IgA class.
7. The antibody described in claim 6, wherein the antibody is of the IgG class and has an IgG1, IgG2, IgG3, or IgG4 isotype.
8. (i) the antibody comprises one or more amino acid substitutions in the Fc region at residue positions selected from the group consisting of C127S, L234A, L234F, L235A, L235E, S267E, K322A, L328F, A330S, P331S, E345R, E430G, S440Y, and any combination thereof, wherein the numbering of said residue positions is according to EU numbering; (ii) the antibody has an IgG4 isotype and contains a S228P amino acid substitution at residue position 228, a L234A amino acid substitution at residue position 234, and a L235A amino acid substitution at residue position 235, wherein the numbering of the residue positions is according to EU numbering; or (iii): (a) the Fc region comprises an amino acid substitution at position E430G, wherein the numbering of said residue positions is according to EU numbering; or (b) the Fc region comprises amino acid substitutions at positions L234A, L235A, and P331S, wherein the numbering of said residue positions is according to EU numbering; or (c) the Fc region comprises amino acid substitutions at positions L234A, L235A, P331S, and E430G, wherein the numbering of said residue positions is according to EU numbering; or (d) the Fc region comprises amino acid substitutions at positions K322A and E430G, wherein the numbering of said residue positions is according to EU numbering; or (e) the Fc region comprises amino acid substitutions at positions P331S and E430G, wherein the numbering of said residue positions is according to EU numbering; or (f) the Fc region comprises amino acid substitutions at positions A330S, P331S, and E430G, wherein the numbering of said residue positions is according to EU numbering; or (g) the Fc region comprises amino acid substitutions at positions K322A, A330S, and P331S, wherein the numbering of said residue positions is according to EU numbering; or (h) the Fc region comprises amino acid substitutions at positions K322A, P331S, and E430G, wherein the numbering of said residue positions is according to EU numbering; or (i) the Fc region comprises an amino acid substitution at position E430G, wherein the numbering of said residue positions is according to EU numbering; or (j) the Fc region comprises amino acid substitutions at positions A330S, P331S, and E430G, wherein the numbering of said residue positions is according to EU numbering; or (k) the Fc region comprises amino acid substitutions at positions S267E and L328F, wherein the numbering of said residue positions is according to EU numbering; or (l) the Fc region comprises an amino acid substitution at position C127S, wherein the numbering of said residue positions is according to EU numbering; or (m) the Fc region comprises amino acid substitutions at positions E345R, E430G, and S440Y, wherein the numbering of said residue positions is according to EU numbering; or (n) the Fc region comprises an amino acid substitution at position P331S, wherein the numbering of said residue positions is according to EU numbering; or (o) the Fc region comprises amino acid substitutions at positions L234A, L235A, and P331S, wherein the numbering of said residue positions is according to EU numbering; The antibody according to any one of claims 1 to 7.
9. (i) the antibody is an antibody fragment that binds to an epitope that includes amino acid residues on human CD33 or cynomolgus CD33 protein; (ii) the antibody is an antibody fragment that binds to one or more human proteins selected from the group consisting of human CD33, naturally occurring variants of human CD33, and disease variants of human CD33; The antibody according to any one of claims 1 to 8.
10. The antibody fragment is crosslinked to a second antibody fragment that binds to one or more human proteins selected from the group consisting of human CD33, naturally occurring variants of human CD33, and disease variants of human CD33, and / or the fragment is a Fab, Fab', Fab'-SH, F(ab')2, Fv, or scFv fragment. The antibody described in claim 9.
11. (i) the antibody has a dissociation constant (K) for human CD33 that is at least 1.8-fold lower than an anti-CD33 antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:4; D ) wherein K D is determined by BioLayer interferometry; (ii) the antibody has a dissociation constant (K) for human CD33 of 200 pM or less than 200 pM; D ) wherein K D is determined by BioLayer interferometry; (iii) the antibody has a median effective concentration (EC) of less than 40 pM as measured by flow cytometry. 50 ) to reduce cell surface levels of CD33 in vitro; and / or (iv) the antibody comprises an Fc region comprising the amino acid sequence of SEQ ID NO: 118; The antibody according to any one of claims 1 to 10.
12. One or more isolated nucleic acids comprising nucleic acid sequences encoding the light and heavy chains of an antibody according to any one of claims 1 to 11.
13. 13. One or more vectors comprising one or more nucleic acids of claim 12.
14. 14. An isolated host cell comprising one or more vectors of claim 13.
15. 15. A method for producing an antibody that binds to CD33, comprising culturing the cells of claim 14 so that the antibody is produced.
16. The method of claim 15, further comprising recovering the antibody produced by the cells.
17. A pharmaceutical composition comprising the antibody of any one of claims 1 to 11 and a pharma- ceutically acceptable carrier.
18. 12. The antibody of any one of claims 1 to 11 for use in a method for preventing, reducing the risk of, or treating a disease, disorder, or injury selected from the group consisting of dementia, frontotemporal dementia, Alzheimer's disease, vascular dementia, mixed dementia, taupathies, infectious diseases, and cancer, comprising administering a therapeutically effective amount of the antibody to an individual in need thereof.
Citation Information
Patent Citations
Anti-cd33 antibody and method of use thereof
JP2018518176A
